

The Warren Alpert Medical School
Curriculum Vitae

Date Prepared: October 1, 2021
Name: Eric T Wong, MD
Office Address: Division of Hematology/Oncology
Department of Medicine
Rhode Island Hospital
593 Eddy Street
Providence, Rhode Island 02903
Work Phone: 401-444-0115
Work Email: EWong1@Lifespan.org
Work Fax: 401-444-4184

Education

1981 – 1985	Bachelor of Science Cum Laude	Electrical Engineering	University of Pennsylvania
-------------	----------------------------------	------------------------	----------------------------

1985 – 1989	Doctor of Medicine	Medicine	Rutgers Medical School
-------------	--------------------	----------	------------------------

Postdoctoral Training

1989 – 1990	Internship	Internal Medicine	New Jersey Medical School
-------------	------------	-------------------	---------------------------

1990 – 1993	Residency	Neurology	Barnes Hospital Washington University Med. Ctr.
-------------	-----------	-----------	--

1993 – 1995	Fellowship	Neuro-Oncology	Memorial Sloan-Kettering Cancer Center
-------------	------------	----------------	---

1995 – 1997	Fellowship	Neuro-Oncology	The University of Texas M.D. Anderson Cancer Center
-------------	------------	----------------	--

Faculty Academic Appointments

1995 – 1997	Junior Faculty Associate	Department of Neuro-Oncology	The University of Texas M.D. Anderson Cancer Center
-------------	-----------------------------	------------------------------	--

1997 – 2009	Assistant Professor	Department of Neurology	Harvard Medical School
-------------	---------------------	-------------------------	------------------------

of Neurology

2009 – 2021	Associate Professor of Neurology	Department of Neurology	Harvard Medical School
2021 –	Professor of Neurology	Departments of Neurology & Medicine	Warren Alpert Medical School of Brown University

Appointments at Hospitals/Affiliated Institutions

Current

1997 – 2021	Staff Neurologist	Department of Neurology Beth Israel Deaconess Med. Ctr.	Boston, Massachusetts
1998 – 2021	Full Member	Beth Israel Deaconess Cancer Center	Boston, Massachusetts
1998 – 2017	Staff Neurologist	South Cove Community Health Center	Boston, Massachusetts
2021 –	Staff Neuro-Oncologist	Department of Neurology & Medicine Rhode Island Hospital	Providence, Rhode Island

Major Administrative Leadership Positions

Local

1997 – 2021	Co-Director, Brain Tumor Center	Beth Israel Deaconess Med. Ctr.
1997 – 2021	Director, Neuro-Oncology Unit	Beth Israel Deaconess Med. Ctr.
2021 –	Director of Medical Neuro-Oncology	Rhode Island Hospital
2021 –	Director of Clinical Neuro-Oncology Research	Rhode Island Hospital

Committee Service

Local

1997 – 2021	Cancer Committee Member	Beth Israel Deaconess Cancer Center Member
2008 – 2009	Scientific Review Committee Member	Dana Farber/Harvard Cancer Center

2009 – 2010 Institutional Review Board, Panel F
Committee Member Dana Farber/Harvard Cancer Center

2009 – Neuro-Oncology Protocol Committee
Committee Member Dana Farber/Harvard Cancer Center

Regional

2009 – Medical Policy Review Committee
Oncology Representative Blue Cross Blue Shield of Massachusetts

National and International

2010 – 2012 Clinical Practice Committee
Massachusetts State Representative American Society of Clinical Oncologists

2013 – J14/JK Carrier Advisory Committee
Committee Member National Government Services
Center for Medicare & Medicaid Services

2015 Study Section Reviewer
Internet Assisted Review National Center for Advancing Translational
Sciences (NCATS)

2018 – 2019 Evidence Street® Request for Clinical Input
Clinical Advisor Blue Cross Blue Shields Association
Chicago, Illinois, USA

2020 – Data Safety Monitoring Board Turning Point Therapeutics
San Diego, California, USA

2020 – Director, Brain Tumor Expert Panel Cancer Commons
Mountain View, California, USA

2021 – Distinguished Lecturer Engineering in Medicine & Biology Society
Institute Electrical & Electronic Engineers

2021 – Protocol Steering Committee OptimalTTF-2, Aarhus University Hospital
Aarhus, Denmark

Professional Societies

1988 – 1995 Society for Neuroscience Member

1991 – 1995 American Association for the
Advancement of Science Member

1993 –	American Academy of Neurology	Member
1994 –	American Association for Cancer Research	Member
1996 –	Society for Neuro-Oncology	Member
1998 –	American Society of Clinical Oncology	Member
2007 –	American Neurological Association	Fellow
2007 –	Massachusetts Society of Clinical Oncologists	
	2007 – 2009	Director
	2009 – 2010	Vice President
	2010 – 2012	President
	2013 –	Carrier Advisory Committee

Editorial Activities

2005 – 2008	Editorial Member Central Nervous System Tumors	Journal of Clinical Oncology
2009 –	Abstract Review Committee Neuro-Oncology	American Neurological Association
2013 –	Associate Editor	Cancer Medicine
	Ad Hoc Reviewer:	American Journal of the Medical Sciences
		Annals of Neurology
		Asia-Pacific Journal of Clinical Oncology
		BMC Cancer
		Cancer Chemotherapy and Pharmacology
		Cancer Research
		Cerebral Cortex
		Expert Review of Anticancer Therapy
		Expert Review of Neurotherapeutics
		International Journal of Cancer

Journal of Immunotherapy

Journal of the National Comprehensive Cancer Network

Journal of Neuro-Oncology

Lancet Oncology

Melanoma Research

Molecular Cancer

Nature Communications

Neoplasia

Neurology

Oncogene

Physics in Medicine & Biology

Translational Oncology

Honors and Prizes

1981	Semi-Finalist	Westinghouse Science Award	Research Award
1986	Letter of Commendation	National Institute of Neurological and Communicative Diseases and Stroke (NINCDS)	Research Award
1988	Saul R. Korey Award for Experimental Neurology	American Academy of Neurology	Research Award
1996	Clinical Trainee Research Award	The University of Texas M. D. Anderson Cancer Center	Research Award
2021	Oncologist of the Year	Massachusetts Society of Clinical Oncologists	Recognition Award

Report of Funded and Unfunded Projects

Funding Information

Past

- 1997 – 1999 DepoTech Corporation: "A Phase IV Multi-Center Clinical Study of DepoFoam™ Encapsulated Cytarabine (DTC101) in the Treatment of Neoplastic Meningitis in Patients with Solid Tumors, including Primary Brain Tumors" (No NCT#)
BIDMC Principal Investigator
To investigate safety and efficacy of a long-acting formulation of cytarabine during the post-marketing surveillance period in patients with neoplastic meningitis from solid tumors
- 1998 – 2000 Sugen Incorporated / Pfizer Incorporated: "A Phase III Randomized Study of SU101 versus Procarbazine for Patients with Glioblastoma Multiforme in First Relapse" (NCT00003293)
BIDMC Principal Investigator.
To investigate the efficacy of a first-in-kind small molecule tyrosine kinase inhibitor in recurrent glioblastoma
- 1998 – 2000 Sugen Incorporated / Pfizer Incorporated: "A Phase II Open Label Study of SU101 for Patients with Anaplastic Astrocytoma in First Relapse" (NCT00003775)
BIDMC Principal Investigator.
To investigate the efficacy of a first-in-kind small molecule tyrosine kinase inhibitor in recurrent anaplastic astrocytoma
- 1999 – 2000 Amgen Incorporated: "A Phase I Trial of Infergen Alternating with Carboplatin and Etoposide in Patients with High-Grade Gliomas" (No NCT#)
BIDMC Principal Investigator.
To investigate the safety of alpha interferon in combination with carboplatin and etoposide in patients with malignant gliomas
- 1999 – 2001 Aguron Pharmaceuticals Incorporated: "A Randomized Double-Blind, Placebo-Controlled Phase II Study of the Matrix Metalloproteinase Inhibitor Prinomastat in Combination with Temozolomide following Radiation Therapy in Patients Having Newly Diagnosed Glioblastoma Multiforme" (NCT00004200)
BIDMC Principal Investigator
To investigate in a registration study the efficacy of a matrix metalloproteinase inhibitor for patients with newly diagnosed glioblastoma
- 2000 – 2004 SkyePharma Incorporated: "A Randomized Clinical Study to Determine the Patient Benefit and Safety of DepoCyt® (Cytarabine Liposome Injection) for the Treatment of Neoplastic Meningitis" (NCT00029523)
BIDMC Principal Investigator
Registration study to investigate safety and efficacy of a long-acting formulation of cytarabine for patients with neoplastic meningitis
- 2003 – 2005 Pharmacyclics Incorporated: "Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients with Non-Small

- Cell Lung Cancer Undergoing Whole Brain Radiation therapy” (NCT00054795)
 BIDMC Principal Investigator
 Registration study to investigate efficacy of a radiation sensitizer motexafin gadolinium for the treatment of brain metastases from non-small cell lung cancer in patients undergoing whole brain radiotherapy
- 2003 – 2004 Celgene Incorporated: “A Pilot Study of Irinotecan, Thalidomide, and Doxycycline Combination Treatment for Recurrent High-Grade Gliomas” (No NCT#)
 BIDMC Investigator-Initiated Trial, CCI #2003-P-000109
 BIDMC Principal Investigator.
 Investigator-initiated study of combination irinotecan, thalidomide and doxycycline for recurrent malignant gliomas
- 2003 – 2005 Pfizer Incorporated: “A Phase III Randomized Open-Label Study of IV Edotecarin versus Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients with Glioblastoma Multiforme that has Progressed/Recurred after Alkylator-Based (Neo)Adjuvant Chemotherapy” (NCT00068952)
 BIDMC Principal Investigator.
 Registration study to investigate a topoisomerase I inhibitor for recurrent glioblastoma
- 2004 – 2008 Neurobiological Technologies Incorporated: “A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone” (NCT00088166)
 BIDMC Principal Investigator
 Registration study of corticosteroid-sparing effect of human corticotropin-releasing factor in patients with brain tumors
- 2004 – 2007 Eastern Cooperative Oncology Group: “A Phase I/III Randomized Study of Radiation Therapy and Temozolomide Versus Radiation Therapy and BCNU for Anaplastic Astrocytoma” (NCT00004259)
 BIDMC Principal Investigator
 To investigate the efficacy of radiation and temozolomide for anaplastic astrocytoma
- 2004 – 2009 Enzon Incorporated: “A Phase II Study of Liposomal Cytarabine (DepoCyt®) and Temozolomide (Temodar®) for Neoplastic Meningitis from Breast Carcinoma” (NCT00515788)
 BIDMC Principal Investigator
 To investigate the efficacy of a longacting formulation of cytarabine for patients with neoplastic meningitis from breast cancer
- 2005 – 2008 Celgene Incorporated: “Phase II Study of Lenalidomide and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma” (NCT00165477)
 BIDMC Co-Investigator
 To investigate the radiation-sensitizing efficacy of lenalidomide in patients with newly diagnosed glioblastoma

- 2005 – 2009 Neurobiological Technologies Incorporated: “An Open-Label, Extended Use Study of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients Who Participated in the Dexamethasone-Sparing Studies NTI 0302 or NTI 0303” (NCT00226655)
 BIDMC Principal Investigator
 Registration study of corticosteroid-sparing effect of human corticotropin-releasing factor in patients with brain tumors
- 2005 – 2009 National Cancer Institute (1R21CA117079-01): “A Phase II Study of AZD2171 in Recurrent Glioblastoma” (NCT00305656)
 BIDMC Co-Investigator
 To investigate the antiangiogenesis effect of pan-vascular endothelial growth factor receptor antagonist AZD2171
- 2006 – 2017 Integrated Therapeutics Incorporated: “Phase I Metronomic Temozolomide for Recurrent Malignant Gliomas, with Correlative 3.0-Tesla Arterial Spin Labeling Perfusion Imaging and CSF Zymography”
 BIDMC Investigator-Initiated Trial, CCI #2006-P-000093 (No NCT#)
 BIDMC Principal Investigator
 To investigate the antiangiogenesis effect of metronomic temozolomide in patients with recurrent malignant glioma
- 2006 – 2010 Eli Lilly and Company: “DFCI #06-097: A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (PREMETREXED), a Novel Anti-Folate” (No NCT#)
 DFCI Co-Investigator
 To assess the safety and to determine the maximum tolerated dose of an anti-folate agent premetrexed for the treatment of central nervous system lymphoma
- 2007 – 2018 AstraZeneca PLC: “DFCI #06-377: Phase I/II Study of ZD6474 (Vandetanib) with Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma” (NCT00441142)
 DFCI Investigator-Initiated Trial
 DFCI Co-Investigator
 To determine the safety and efficacy of multi-kinase inhibitor vandetanib in patients with newly diagnosed glioblastoma
- 2007 – 2010 Celldex Therapeutics: “DFCI #07-179: A Phase II Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme” (NCT00458601)
 DFCI Co-Investigator
 To assess the efficacy of an anti-EGFRvIII vaccine CDX-110 in patients with newly diagnosed glioblastoma
- 2007 – 2010 Novocure Limited: “DFCI #07-306: A Prospective, Multi-Center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients with Progressive or Recurrent Glioblastoma Multiforme” (NCT00379470)
 DFCI Principal Investigator
 Registration study of Tumor Treating Fields for patients with recurrent glioblastoma

- 2007 – 2016 Cephalon Incorporated: “DFCI #07-341: A Randomized Placebo-Controlled Trial of Armodafinil (Nuvigil) for Fatigue in Patients with Malignant Gliomas Undergoing Radiotherapy with or Without Standard Chemotherapy Treatment” (NCT00766467)
DFCI Co-Investigator.
To determine the efficacy of a sympathomimetic armodafinil for the treatment of fatigue in patients with malignant gliomas undergoing radiotherapy
- 2008 – 2010 Adnexus / Bristol-Myers Squibb R&D Company: “DFCI #07-279: Phase II, 2-Part, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of CT-322 (Angiocept™) Monotherapy and Combination Therapy with Irinotecan in Patients with Recurrent Glioblastoma Multiforme”
DFCI Co-Investigator
To investigate a recombinant monoclonal antibody against vascular endothelial growth factor receptor 2 in patients with recurrent glioblastoma
- 2009 – 2010 National Cancer Institute / Adult Brain Tumor Consortium: “DFCI #08-108: Phase I Trial of Aflibercept (VEGF Trap) with Radiation therapy and Concomitant and Adjuvant Temozolomide in Patients with Malignant Glioma” (NCT00650923)
DFCI Co-Investigator
To investigate the efficacy of antiangiogenesis recombinant receptors aflibercept against vascular endothelial growth factor
- 2009 – 2017 Novartis Oncology: “DFCI #08-266: Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma” (NCT00859040)
DFCI Investigator-Initiated Trial
DFCI Co-Investigator
To investigate a somatostatin 5 inhibitor SOM230C in patients with advanced meningioma
- 2009 – 2017 Exelixis: “DFCI #09-291: A Phase 2 Study of XL184 in Subjects with Progressive or Recurrent Glioblastoma Multiforme in First or Second Relapse” (NCT00704288)
DFCI Co-Investigator
To investigate the efficacy of a multi-kinase inhibitor of hepatocyte growth factor receptor and vascular endothelial growth factor receptor 2 in patients with recurrent glioblastoma
- 2009 – 2018 Pfizer Oncology: “DFCI #09-468: An Open-Label, Phase 2 Trial of Orally Administered PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (GBM)” (NCT01112527)
Massachusetts General Hospital Investigator-Initiated Trial
DFCI Co-Investigator
To investigate the efficacy of an irreversible pan-epidermal growth factor receptor inhibitor in patients with recurrent glioblastoma
- 2010 – 2015 National Institutes of Health (1R01CA115745-01A1): “Blood Flow MRI for Monitoring Glioma Angiogenesis” (NCT01538264)
BIDMC Co-Investigator
To investigate the utility of arterial spin labeling blood flow MRI in patients with gliomas

- 2011 – 2018 Incyte Corporation: “DFCI #11-314: A phase I, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies” (NCT01375842)
DFCI Co-Investigator
To determine the maximum tolerated dose of a PDL-1 checkpoint inhibitor MPDL3280A in recurrent glioblastoma
- 2013 – 2017 Novartis Oncology: “DFCI #08-342: Phase I/II Study of LBH589 and Bevacizumab in Patients with Recurrent High Grade Glioma” (NCT00859222)
DFCI Investigator-Initiated Trial
DFCI Co-Investigator
To determine the maximum tolerated dose of a pan-histone deacetylase inhibitor LBH589 in combination with bevacizumab in patients with recurrent malignant gliomas
- 2015 – 2018 Vascular Biogenics Limited: “DFCI #15-573: A Phase 3, Randomized, Controlled, Double-Arm, Open- Label, Multi-center Study of VB-111 Combined with Bevacizumab vs. Bevacizumab Monotherapy in Patients with Recurrent Glioblastoma” (NCT02511405)
DFCI Co-Investigator
Pivotal registration trial to test the efficacy of antiangiogenic gene therapy agent VB-111 in patients with recurrent glioblastoma

Current

- 2013 – Plexxicon: “DFCI #13-247: An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients with Newly Diagnosed Glioblastoma” (NCT01790503)
DFCI Co-Investigator, \$60,886
To determine the efficacy of PLX3397, a colony stimulating factor-1receptor inhibitor that blocks tumor-associated macrophages, in newly diagnosed glioblastoma patients
- 2013 – Northwest Biotherapeutics: “DFCI #13-354: A phase III clinical trial evaluating DCVax-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)” (NCT00045968)
DFCI Co-Investigator, \$88,793
To determine the safety and efficacy of dendritic cell vaccine DCVax-L in newly diagnosed glioblastoma patients
- 2014 – Northwest Biotherapeutics: “DFCI #14-483: An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients with Already Manufactured DCVax-L Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221” (NCT02146066)
DFCI Co-Investigator, \$0
To determine the safety and efficacy of dendritic cell vaccine DCVax-L in newly diagnosed glioblastoma patients

- 2015 – Five Prime Therapeutics Incorporated: “DFCI #15-572: A Phase 1a/1b Study of FPA008 in Combination with Nivolumab in Patients with Selected Advanced Cancers” (NCT02526017)
DFCI Co-Investigator, \$4,783
To determine the toxicity of FPA008, a colony stimulating factor-1receptor inhibitor that blocks tumor-associated macrophages, in combination with checkpoint inhibitor nivolumab
- 2016 – National Cancer Institute: “DFCI #16-138: A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma” (NCT02455557)
DFCI Co-Investigator, \$25,434
To determine the efficacy of SVN53-67/M57-KLH (SurVaxM) vaccine
- 2016 – Novocure Limited: “DFCI #16-459: Pivotal, Open-Label, Randomized Study of Radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-Small Cell Lung Cancer (NSCLC)” (NCT02831959)
DFCI Overall Principal Investigator, \$20,762
To compare Tumor Treating Fields versus observation after radiosurgery treatment for brain metastases from non-small cell lung cancer
- 2016 – Orbus Therapeutics Incorporated: “DFCI #16-517: A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy” (NCT02796261)
DFCI Overall Principal Investigator, \$20,844
Pivotal registration trial on the efficacy of eflornithine, an irreversible inhibitor of ornithine decarboxylase, for patients with recurrent anaplastic astrocytoma
- 2018 – Merck Incorporated: “DFCI #18-277: Phase II Trial of Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma” (NCT03661723)
DFCI Co-Investigator, \$20,000
To determine the efficacy of pembrolizumab against recurrent glioblastoma after radiation sensitization
- 2018 – Sanofi Aventis Research & Development: “DFCI #18-332: A Phase 1/2 Open-Label, Multi-Center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination with Atezolizumab or Isatuximab Alone in Patients with Advanced Malignancies” (NCT03637764)
DFCI Co-Investigator, \$500
To determine the efficacy of anti-CD38 monoclonal antibody isatuximab in patients with advance malignancies, including recurrent glioblastoma
- 2018 – Novocure Limited: “DFCI #18-615: Phase I and II Study of NovoTTF-200A and Pembrolizumab in Newly Diagnosed Melanoma Brain Metastasis” (NCT04129515)
BIDMC Investigator-Initiated Trial
DFCI Overall Principal Investigator, \$150,000

To determine the safety and efficacy of Tumor Treating Fields in combination with checkpoint inhibitor pembrolizumab for brain metastases from malignant melanoma

**Current
(Other)**

- 2010 – NovoCure Limited: “Cell Biology Effects of NovoTTF-100A Alternating Electric Fields”
Sponsored Laboratory Research Program
BIDMC Principal Investigator, \$359,053
To investigate the cell biology effects of alternating electric fields that have anti-cancer efficacy
- 2018 – National Cancer Institute (1R01CA229784-01): “Advancing Treatment Outcomes in Malignant Glioma by Integrating Immunotherapy and Standard of Care using Genetically Engineered Mice that Recapitulate Molecular Features of Human Glioma”
BIDMC Co-Investigator, \$10,000
- 2019 – American Association for Cancer Research–Bayer Innovation and Discovery Grant: “CSF Metabolomic Biomarkers to Predict CNS Response to Cancer Immunotherapy”
BIDMC Principal Investigator, \$50,000
To determine metabolomic biomarkers in the cerebrospinal fluid of cancer patients to predict the effect of immunotherapy
- 2019 – Musella Foundation: “Computer Modeling of Tumor Treating Fields in the FORWARD Trial”
BIDMC Principal Investigator, \$50,000
To correlate the electric field intensity within the grade II or III malignant glioma in patients enrolled in the FORWARD trial

Current Unfunded Projects

- 2012 – National Cancer Institute (1R21CA169860-01): “Cerebrospinal Fluid Immunokine and Metabolomic Profiles for Brain Tumors”
- 2012 – Department of Defense (LC110586): “Cerebrospinal Fluid Cytokines and Chemokines for Lung Cancer Brain Metastasis”

Report of Local Teaching and Training

Teaching of Students in Courses

- | | | |
|--------|--|---|
| 1997 - | Neurological Examination
HMS Students | Harvard Medical School
Annual Single Lecture |
|--------|--|---|

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

1998 –	Brain Tumor Conference Residents or Fellows in Neurology, Neurosurgery, Radiation Oncology, Neuropathology, and Neuroradiology	Beth Israel Deaconess Medical Center Weekly 2-Hour Meeting
2000 –	Monthly Didactic Lecture in Neuro- Oncology Neurology Residents	Beth Israel Deaconess Medical Center Monthly 1-Hour Case Presentation
2008 – 2011	Diagnosis and Treatment of Malignant Gliomas Neuroradiology Fellows	Beth Israel Deaconess Medical Center Annual Single Lecture
2008	The Story Behind Bevacizumab plus Irinotecan for Glioblastomas Neurology Residents and	Beth Israel Deaconess Medical Center Single Lecture
2009	Neuro-Oncology Teaching Conference Hematology/Oncology Fellows	Beth Israel Deaconess Medical Center Monthly Lecture Series
2011	Antiangiogenesis Treatment for Malignant Gliomas and Vascular MRI Neuroradiology Fellows	Beth Israel Deaconess Medical Center Single Lecture
2013 –	Neurological Complication of Cancer Hematology/Oncology Fellows	Beth Israel Deaconess Medical Center Annual Orientation Summer Lecture Series
2013 –	Neurological Complication of Cancer Neurology Residents	Beth Israel Deaconess Medical Center Yearly Lecture Series
2013 –	Management of Primary Brain Tumors Hematology/Oncology Fellows	Beth Israel Deaconess Medical Center Annual Winter Lecture Series
2013 –	Management of Primary Brain Tumors Neurology Residents	Beth Israel Deaconess Medical Center Yearly Lecture Series

Clinical Supervisory and Training Responsibilities

2005 – Supervise Medicine Residents for Lumbar Puncture Procedures
Beth Israel Deaconess Medical Center

Laboratory and Other Research Supervisory and Training Responsibilities

2009-2013 Amy Chung, B.S.
University of New England Medical
Student Supervised Research Career in Laboratory
and Clinical Sciences

Formally Supervised Trainees

- 2010 – 2012 Edwin Lok, M.S., Supervised Training for Master Thesis
 Master of Science in Radiological Science and Protection: “Prediction of Clinical Outcomes by Chemokines and Cytokines Profiling in CSF from Radiation Treated Breast Cancer Primary with Brain Metastases”
 Chief of Radiation Physics, Brockton Hospital, Brockton, Massachusetts
- 2011 – 2013 Ekokobe Fonkem, M.D., Supervised Training for Neuro-Oncology Fellowship
 Scott & White Medical Center, Temple, Texas
 Texas A & M School of Medicine, College Station, Texas
 Assistant Professor of Medicine
- Barrow Neurological Institute, Pheonix, Arizona
 University of Arizona
 Associate Professor of Neurology
- 2015 – 2016 Kester Phillips, M.D., Supervised Training for Neuro-Oncology Fellowship
 Inova Hospital, Fairfax, Virginia
- Ben and Catherine Ivy Center for Advanced Brain Tumor Treatment
 Swedish Medical Center Foundation, Seattle, Washington
- 2018 – 2020 Sasmit Sarangi, M.D., Supervised Training for Neuro-Oncology Fellowship
 Rhode Island Hospital, Providence, Rhode Island
 Warren Alpert School of Medicine at Brown University
 Assistant Professor of Neurology

Formal Teaching of Peers (e.g., CME and other continuing education courses)

- | | | |
|-----------|--|---|
| 2007-2011 | Chemotherapy for Patients with Gliomas
Fifteen Annual Tumor of the Central Nervous System | Single Annual Presentation
Boston, Massachusetts |
| 2007 | Neuro-Oncology & Neuro-Imaging
Massachusetts Medical Society | Waltham, Massachusetts |
| 2014 | “Low Grade Gliomas”
Neuro-Oncology CME Course: Update on CNS Tumors in Adults
May 10, 2014 | Boston, Massachusetts |
| 2014 | At A Turning Point: Novel Therapeutic Developments in Glioblastoma Multiforme (GBM) Research
Satellite Meeting to the 19th Annual Meeting of the Society for Neuro-Oncology | Miami, Florida |

November 12, 2014

- | | | |
|------|---|-----------------------|
| 2015 | At A Turning Point: Novel Therapeutics
Developments in Glioblastoma Multiforme
(GBM) Research
Satellite Meeting to the 20 th Annual Meeting
of the Society for Neuro-Oncology
November 19, 2015 | San Antonio, Texas |
| 2016 | “Low Grade Gliomas”
Neuro-Oncology CME Course: Adult
Neuro-Oncology, Biology and Treatment
Update
December 10, 2016 | Boston, Massachusetts |
| 2017 | Meeting Co-Chair
Inovitro (Tumor Treating Fields) User
Meeting
February 16 & 17, 2017 | Hollywood, Florida |
| 2018 | “Tumor Treating Fields for Glioblastoma
and Other Malignancies”
Chair
Interactive Lunch Workshop
143 rd Annual Meeting of the American
Neurological Association
October 22, 2018 | Atlanta, Georgia |

Report of Regional, National and International Invited Teaching and Presentations

Invited Presentations and Courses

Local/Regional

- 1999 “Treatment of High-Grade Gliomas: Past, Present, and Future”
Grand Rounds, Department of Neurology Boston, University School of Medicine
Boston, Massachusetts, January 19, 1999
- 1999 “A 61-year-old man was admitted to the hospital because of transient quadriplegia and apnea”
Case Record of the Massachusetts General Hospital
Boston, Massachusetts, September 30, 1999
- 2000 “Brain Tumors”
Hematology/Oncology Grand Round, Caritas Norwood Hospital
Norwood, Massachusetts, May 17, 2000
- 2000 “Brain Tumor Update: Targeting Metastases and Primary Brain Tumors”
Hematology/Oncology Grand Round,
Norris Cotton Cancer Center/Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, August 24, 2000
- 2001 “Treatment of Refractory Anaplastic Astrocytomas and Glioblastoma Multiforme”
Hematology/Oncology Grand Round, Boston Veterans Affairs Medical Center
Boston, Massachusetts, January 8, 2001
- 2002 “Brain Tumor Update: Diagnosis and Management of Primary Brain Tumors”
Hematology/Oncology Grand Round, Maine Medical Center
Portland, Maine, April 30, 2002
- 2003 “Brain Tumor Update”
Hematology/Oncology Grand Round, Maine Medical Center
Portland, Maine, September 16, 2003
- 2004 “Diagnosis and Treatment of Leptomeningeal Metastasis in Cancer Patients”
Hematology/Oncology Grand Round, Mount Auburn Hospital
Cambridge, Massachusetts, January 30, 2004
- 2004 “Emerging Diagnostic and Therapeutic Options for Malignant Gliomas”
Neurology Grand Round, Rhode Island Hospital/Brown University Medical School, Providence,
Rhode Island, September 15, 2004
- 2005 “Immunochemotherapy for Central Nervous System Lymphomas: A New Treatment Paradigm”
Grand Rounds, Longwood Neurology, Harvard Medical School
Boston, Massachusetts, October 26, 2005

- 2006 “Brain Tumor Update”
Hematology/Oncology Grand Round, Maine Medical Center
Portland, Maine, February 14, 2006
- 2006 “Immunochemotherapy for Central Nervous System Lymphomas: A New Treatment Paradigm”
Grand Round, Department of Neurology, New England Medical Center
Boston, Massachusetts, February 23, 2006
- 2006 “New Treatments for Brain Tumors”
Grand Round, Beth Israel Deaconess Medical Center Needham
Needham, Massachusetts, June 7, 2006
- 2006 “Diagnosis and Treatment of Malignant Gliomas: Past, Present, and Future”
Neurology Grand Round, Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, July 21, 2006
- 2006 “New Treatments for Brain Tumors”
Grand Round, Lenoard Morse Hospital
Natick, Massachusetts, November 27, 2006
- 2007 “Stereotactic Radiosurgery for Brain Tumors, A Neuro-Oncologist’s Perspective”
Brain Tumor Conference, Brigham & Women’s Hospital
Boston, Massachusetts, January 5, 2007
- 2007 “New Treatments for Brain Tumors”
Grand Round, Anna Jacques Hospital
Newburyport, MA, March 13, 2007
- 2007 “New Treatments for Brain Tumors”
Grand Round, Nashoba Valley Medical Center
Ayer, Massachusetts, May 15, 2007
- 2007 “Current Concept in the Diagnosis and Treatment of Neoplastic Meningitis”
Grand Round, Northern Maine Medical Center
Fort Kent, Maine, August 8, 2007
- 2007 “Neoplastic Meningitis: Biomarkers and New Treatment Paradigm”
Good Samaritan Medical Center
Brockton, Massachusetts, October 17, 2007
- 2007 “Neuro-Oncology & Neuro-Imaging”
Massachusetts Medical Society
Waltham, Massachusetts, November 10, 2007
- 2007 “Chemotherapy for Patients with Gliomas”
Fifteen Annual Tumors of the Central Nervous System, Brain Tumor Management
Harvard Medical School Continuing Education

- “Chemotherapy for Patients with Gliomas”
Boston, Massachusetts, December 3-4, 2007
- 2008 “The Story Behind Bevacizumab plus Irinotecan for Glioblastomas”
Combined Neurology and Hematology/Oncology Conference for Residents and Fellows
Beth Israel Deaconess Medical Center
Boston, Massachusetts, January 2, 2008
- 2008 “Tumor Biomarkers in Cerebrospinal Fluid”
Hematology/Oncology Retreat, The Eliot House
Dedham, Massachusetts, March 9, 2008
- 2008 “Diagnosis and Treatment of Malignant Gliomas”
Neuroradiology Fellow Conference, Beth Israel Deaconess Medical Center
Boston, Massachusetts, March 11, 2008
- 2008 “Treatment Advances for Glioblastoma Multiforme”
Neurosurgery Grand Round, Boston University Medical Center
Boston, Massachusetts, March 31, 2008
- 2008 “Chemotherapy for Patients with Gliomas”
Sixteen Annual Tumors of the Central Nervous System, Brain Tumor Management
Harvard Medical School Continuing Education
Boston, Massachusetts, December 1-2, 2008
- 2008 “Innovative Therapies for Glioblastoma Multiforme: Antiangiogenesis Treatments and Biomarkers”
Eighteenth Annual Cancer Symposium
George Sagar Memorial Lecture, Maine Medical Center
Portland, Maine, May 21, 2008
- 2008 “Heart and Brain Health”
The Multicultural Coalition on Aging, Tufts Health Plan
Watertown, Massachusetts, October 18, 2008
- 2009 “Diagnosis and Treatment of Malignant Gliomas”
Neuroradiology Fellow Conference, Beth Israel Deaconess Medical Center
Boston, Massachusetts, March 19, 2009
- 2009 “Chemotherapy for Patients with Gliomas”
Seventeen Annual Tumors of the Central Nervous System, Brain Tumor Management
Harvard Medical School Continuing Education
Boston, Massachusetts, December 7-8, 2009
- 2010 “Diagnosis and Treatment of Malignant Gliomas”
Neuroradiology Fellow Conference, Beth Israel Deaconess Medical Center
Boston, Massachusetts, March 18, 2010

- 2010 “Biomarkers for Malignant Gliomas: A Step Closer to Personalized Medicine”/
Cancer Center Faculty Research Seminar, Beth Israel Deaconess Medical Center
Boston, Massachusetts, July 26, 2010
- 2010 “Biomarkers for Malignant Gliomas: A Step Closer to Personalized Medicine”
Monte Jade New England Annual Meeting
Cambridge, Massachusetts, September 25, 2010
- 2010 “Chemotherapy for Patients with Gliomas”
Eighteen Annual Tumors of the Central Nervous System, Brain Tumor Management
Harvard Medical School Continuing Education
Boston, Massachusetts, December 6-7, 2010
- 2011 “Antiangiogenesis Treatment for Malignant Gliomas and Vascular MRI”
Neuroradiology Fellow Lecture, Beth Israel Deaconess Medical Center
Boston, Massachusetts, February 15, 2011
- 2011 “Diagnosis and Treatment of Malignant Gliomas”
Neuroradiology Fellow Conference, Beth Israel Deaconess Medical Center
Boston, Massachusetts, November 22, 2011
- 2011 “Chemotherapy for Patients with Gliomas”
Nineteen Annual Tumors of the Central Nervous System, Brain Tumor Management
Harvard Medical School Continuing Education
Boston, Massachusetts, December 5-6, 2011
- 2012 “Treatment of Malignant Gliomas: Fallacies & Hope”
Neurology Grand Round, Tufts Medical Center
Boston, Massachusetts, December 20, 2012
- 2013 “Low Grade Gliomas”
Tumors of the CNS: Practical Advances in the Care of Primary and Metastatic Brain Tumor
Patients, Dana Farber Cancer Institute
Boston, Massachusetts, May 4, 2013
- 2013 “Contemporary Management of Glioblastoma”
“Examining the Role of a Fourth Treatment Modality: Tumor Treating Fields (TTF)”
PrIME Oncology
Boston, Massachusetts, October 3, 2013
- 2014 “Chemomimetic Effects of Intermediate Frequency Alternating Electric Fields: Another
Crossroad of Physics and Cancer Treatment”
Physics Colloquium, University of Massachusetts in Lowell
Lowell, Massachusetts, February 12, 2014
- 2014 “Low Grade Gliomas”
Update on Central Nervous System Tumors in Adults
Massachusetts General Hospital

Boston, Massachusetts, May 4, 2014

- 2015 “Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality”
Neuroscience Grand Round, Tufts Medical Center
Boston, Massachusetts, February 19, 2015
- 2015 “Sensitivity Analysis of Permittivity and Conductivity on Alternating Electric Fields Therapy for Recurrent Glioblastoma”
Eastern Neuroradiology Society 27th Annual Meeting
Newport, Rhode Island, September 4, 2015
- 2018 “Update on the Management of Malignant Gliomas”
Beth Israel Deaconess Hospital Plymouth
Plymouth, Massachusetts, June 22, 2018
- 2018 “Central Nervous System Metastasis from Pancoast Tumor (NSCLC)”
Neurology Didactic Lecture
Harvard Medical School
Boston, Massachusetts, October 10, 2018
- 2019 “Update on the Management of Malignant Gliomas”
Medicine Grand Round
Harvard University Health Services
Cambridge, Massachusetts, February 13, 2019
- 2021 “Tumor Treating Fields for the Management of Glioblastoma (Brain Cancer)”
Live Webcast: Distinguish Lecturer, International Electrical and Electronic Engineers -
Engineering in Medicine and Biology Society
Wenworth Institute of Technology
Boston, Massachusetts, July 1, 2021
- 2021 “Update on Brain Tumors”
Best of American Society of Clinical Oncology (ASCO) Annual Meeting 2021
Rhode Island Hospital / Brown Cancer Center
Providence, Rhode Island, October 2, 2021

National

- 1998 “Diagnosis and Management of Leptomeningeal Metastasis in Cancer Patients”
Grand Round, University of Maryland Greenbaum Cancer Center
Baltimore, Maryland, February 27, 1998
- 1999 “Diagnosis and Management of Leptomeningeal Metastasis in Cancer Patients”
Hematology/Oncology Grand Round, State University of New York at Stony Brook
Stony Brook, New York, September 8, 1999

- 1999 “Diagnosis and Management of Leptomeningeal Metastasis in Cancer Patients”
Hematology/Oncology Grand Round, North Shore University Hospital/Long Island Jewish Health System
Manhasset, New York, November 18, 1999
- 1999 “Diagnosis and Management of Leptomeningeal Metastasis in Cancer Patients”
Neurology Grand Round, New Jersey Neuroscience Institute at JFK Medical Center/Seton Hall University
Edison, New Jersey, December 22, 1999
- 1999 “Diagnosis and Management of Leptomeningeal Metastasis in Cancer Patients”
Hematology/Oncology Grand Round, Montefiore Medical Center/Albert Einstein College of Medicine
Bronx, New York, December 23, 1999.
- 2001 “Treatment of High-Grade Gliomas: Past, Present, and Future”
Neurology Grand Round, Georgetown University Medical Center
Washington, District of Columbia, April 19, 2001
- 2001 “Diagnosis and Management of Leptomeningeal Metastasis in Cancer Patients”
Visiting Professorship, University of California at Irvine
Irvine, California, April 22-23, 2001
- 2004 “New Advances in the Treatment of Lymphomas, with Special Attention to Central Nervous System Lymphomas”
Hematology/Oncology Grand Round, East Orange Veterans Administration Medical Center/New Jersey Medical School
East Orange, New Jersey, September 8, 2004
- 2004 “Management of Central Nervous System Lymphoma”
Neurology Grand Round, New Jersey Neuroscience Institute at JFK Medical Center/Seton Hall University,
Edison, New Jersey, October 20, 2004
- 2005 “Emerging Diagnostic and Therapeutic Options for Malignant Gliomas”
Hematology/Oncology Grand Round, New York Medical College
Valhalla, New York, February 17, 2005
- 2005 “Immunochemotherapy for Central Nervous System Lymphomas: A New Treatment Paradigm”
Neurology Grand Round, Medical College of Georgia
Augusta, Georgia, November 3, 2005
- 2005 “Immunochemotherapy for Central Nervous System Lymphomas: A New Treatment Paradigm”
Hematology/Oncology Grand Round, University of Cincinnati Medical Center
Cincinnati, Ohio, November 18, 2005

- 2006 “Immunochemotherapy for Central Nervous System Lymphomas: A New Treatment Paradigm”
Neurology Grand Round, Medical University of South Carolina at Charleston
Charleston, South Carolina, March 2, 2006
- 2006 “Diagnosis and Treatment of Malignant Gliomas: Past, Present, and Future”/ Neurology
Grand Round
Neurology grand Round, University of Louisville Medical Center
Louisville, Kentucky, May 16, 2006
- 2007 “Diagnosis and Treatment of Malignant Gliomas: Past, Present, and Future”
Neurology Grand Round, University of Kentucky Medical Center
Lexington, Kentucky, May 17, 2006
- 2007 “Biomarkers for Malignant Gliomas”
Neuro-Oncology Grand Round, Moffitt Cancer Center
Tampa, Florida, March 9, 2007
- 2007 “Current Concept in the Diagnosis and Treatment of Neoplastic Meningitis”
Hematology/Oncology Grand Round, Penn State Milton S. Hersey Medical Center
Hersey, Pennsylvania, September 10, 2007
- 2008 “Lymphomatous Meningitis: Biomarkers, Neuroimaging, and Treatment”/Division of
Hematology/Oncology
Visiting Professorship
Division of Hematology/Oncology, University of Cincinnati Medical Center
Cincinnati, Ohio, February 20-22, 2008
- 2010 “Navigating Through Insurance Companies with Cancer or Catastrophic Illness”
Chinese Center of Long Island
Holtsville, New York, May 21, 2010
- 2011 “Glioblastoma: Tumor Biology, Treatment, and Diet”
Faculty Seminar, Department of Pharmaceutical Sciences, North Dakota State University
Fargo, North Dakota, September 29, 2011
- 2012 “Treatment of Glioblastoma: Have We Made Progress?”
Neurology Grand Round, New York University Langone Medical Center
New York, New York, February 14, 2012
- 2012 “Mitotic Interference by TTFields in Anaphase”
Semi-Annual Meeting, Radiation therapy Oncology Group
Philadelphia, Pennsylvania, June 15, 2012
- 2012 “Disruption of Cell Division During Anaphase by TTFields”
The Seventeenth Annual Meeting of the Society for Neuro-Oncology
Washington, District of Columbia, November 17, 2012

- 2013 “The Clinical Efficacy of TTFields Therapy Against Recurrent Glioblastoma”
Center for Cell Death & Differentiation Symposium, Translational Neurology: From
Neuro-Oncology to Neuro-Immunology and Neuromuscular Disease
The University of Texas A & M School of Medicine, Scott & White Health Care
Temple, Texas, September 11-13, 2013
- 2013 “Evolving Preclinical and Clinical Experiences with Tumor Treating Fields (TTFields)”
Cleveland Clinic 15th Annual Brain Tumor Update and 4th International Symposium on
Long-Term Control of Metastases to the Brain and Spine
Las Vegas, Nevada, November 9-10, 2013
- 2013 “Examining the Role of a Fourth Treatment Modality: Tumor Treating Fields (TTF)”
PrIME Oncology
Sugarland, Texas, December 3, 2013
- 2014 “Treatment of Malignant Gliomas Using Chemomimetic Alternating Electric Fields
Therapy”
Neuroscience Grand Round, Tufts Medical Center
Boston, Massachusetts, January 23, 2014
- 2014 “Examining the Role of a Fourth Treatment Modality: Tumor Treating Fields (TTF)”
PrIME Oncology
St. Louis, Missouri, May 8, 2014
- 2014 “Dexamethasone Exerts Profound Interference to NovoTTF-100A Alternating Electric
Fields Therapy for Recurrent Glioblastoma”
Neurology Grand Round, University of Louisville
Louisville, Kentucky, September 18, 2014
- 2014 “Dexamethasone Exerts Profound Interference on NovoTTF-100A Efficacy for Recurrent
Glioblastoma”
At a Turning Point: Novel Therapeutic Developments in Glioblastoma Multiforme (GBM)
Research
Satellite Meeting to the 19th Annual Meeting of the Society for Neuro-Oncology
Miami, Florida, November 12, 2014
- 2014 “Current State-of-the-Art Therapy for Glioblastoma (GBM)”
PrIME Oncology
Miami, Florida, November 15, 2014
- 2015 “Tumor Treating Fields and Immune Effector Function”
Brain Tumor Doctor-Patient Symposium
American Society of Neuroradiology 53rd Annual Meeting
Chicago, Illinois, April 26, 2015
- 2015 “Treatment for Malignant Glioblastoma Using Alternating Electric Fields Therapy”
Neuro-Oncology Clinical Trials Symposium
The Long Island Brain Tumor Center

DeMatteis Center, St. Francis Hospital
Greenvale, New York, May 15, 2015

- 2015 “Use of Alternating Electric Fields for Glioblastoma: From Towne to Penn Medicine”
Neurosurgery Grand Round
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania, August 6, 2015
- 2015 “Paraneoplastic Syndrome: Diagnosis and Approach to Management”
Neurology Resident Teaching Conference
Cedar-Sinai Medical Center
Los Angeles, California, September 18, 2015
- 2015 “Treatment of Malignant Glioma Using Alternating Electric Fields Therapy”
Neurosurgery Grand Round
Cedar-Sinai Medical Center
Los Angeles, California, September 18, 2015
- 2016 “Technologies in GBM”
34th Annual Chemotherapy Foundation Symposium
New York, New York, November 10, 2016
- 2017 “Electric Field Therapy: The Scientific Rationale and Practical Application”
Neuro-Oncology symposium, Brain Tumors 2017
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania, June 9, 2017
- 2017 “Electric Field Therapy: The Scientific Rationale and Practical Application”
12th Annual New Orleans Summer Cancer Meeting
New Orleans, Louisiana, July 21, 2017
- 2018 “Cancer Treatment Using Tumor Treating Fields: From Zero to One”
Central Texas Neuro-Oncology Symposium
Baylor Scott & White Health
Round Rock, Texas, September 22, 2018
- 2019 “Advances in the Management of Glioblastoma and other Brain Tumors”
8th Annual Puerto Rico Winter Cancer Symposium 2019
San Juan, Puerto Rico, March 2, 2019
- 2019 “Brain Tumors”
16th Annual Miami Cancer Meeting
Miami, Florida, March 29, 2019
- 2021 Virtual Legislative Briefing
Massachusetts Fail First Coalition
Boston, Massachusetts, October 13, 2021

International

- 2008 “Treatment Advances for Glioblastoma Multiforme”
Huashan Hospital, Fudan University
Shanghai, China, May 8, 2008
- 2008 “Treatment Advances for Glioblastoma Multiforme”
Hisun Pharmaceuticals, Ltd.
Taizhou City, China, May 15, 2008
- 2008 “Treatment Advances for Glioblastoma Multiforme”
Shanghai Second Medical University
Shanghai, China, May 16, 2008
- 2009 Neurosurgery Department Seminar
“Treatment of Malignant Gliomas: Cerebrospinal Fluid Biomarkers and Drug
Development”
Shandong Provincial Hospital, Shandong University
Shandong, China, October 23, 2009
- 2012 The Thirteenth Annual Meeting of the Japan Society for Neuro-Oncology
“Disruption of Cell Division During Anaphase by TTFIELDS”
Hiroshima, Japan, November 25, 2012
- 2013 Live International Teleconference: Brain Tumor Foundation & CancerCare
Teleconference “Update on Glioblastoma”
CancerCare
New York, New York, March 23, 2013
- 2014 The Sixteenth Biennial Canadian Neuro-Oncology Meeting 2014
“NovoTTF-100A Alternating Electric Fields Therapy for Recurrent Glioblastoma: An
Analysis of Patient Registry Data”
Pier 21, Halifax, Nova Scotia, June 14, 2014
- 2014 Eleventh Meeting of The European Association of Neuro-Oncology (EANO)
“NovoTTF-100A Alternating Electric Fields Therapy for Recurrent Glioblastoma: An
Analysis of Patient Registry Data”
Lingotto Conference Center, Turin, Italy, October 11, 2014
- 2015 The 13th International Symposium on Computer Methods in Biomechanics and Biomedical
Engineering (CMBBE)
“Disposition Analysis of Computed Modeling of Alternating Electric Fields Therapy for
Recurrent Glioblastoma”
Hyatt Regency, Montreal, Canada, September 3, 2015
- 2015 The 13th International Symposium on Computer Methods in Biomechanics and
Biomedical Engineering (CMBBE)

- “Alternating Electric Fields Therapy for Malignant Gliomas: From Bench Observation to Clinical Reality”
Hyatt Regency, Montreal, Canada, September 3, 2015
- 2016 Live International Teleconference: Brain Tumor Foundation & CancerCare Teleconference
“Update on Glioblastoma”
CancerCare
New York, New York, March 24, 2016
- 2017 2017 Chinese Society for Neuro-Oncology-Society for Neuro-Oncology Joint Meeting
“How to Run A Clinical Trial in Neuro-Oncology”
Guangzhou, China, February 24, 2017
- 2017 2017 Chinese Society for Neuro-Oncology-Society for Neuro-Oncology Joint Meeting
“Tumor Treating Fields for Malignant Gliomas”
Guangzhou, China, February 25, 2017
- 2017 Live International Teleconference: Brain Tumor Foundation & CancerCare Teleconference
“Update on Glioblastoma”
CancerCare
New York, New York, March 23, 2017
- 2018 Live International Teleconference: Brain Tumor Foundation & CancerCare Teleconference
“Update on Glioblastoma”
CancerCare
New York, New York, January 11, 2018
- 2018 Live International Webcast: Brain Tumor Awareness Month 2018 Webinar Series
Musella Foundation for Brain Tumor Research & Information
Hewlett, New York, May 27, 2018
- 2018 XIXth International Congress of Neuropathology
“TTFields for Glioblastoma: From Cell Biology to Clinical Applications”
Tokyo, Japan, September 26, 2018
- 2019 Live International Teleconference: Brain Tumor Foundation & CancerCare Teleconference
“Update on Glioblastoma in Adults”
CancerCare, New York, New York, February 21, 2019
- 2019 Medical Oncology Grand Round, Queen Elizabeth Hospital
“Tumor Treating Fields: A Fifth Modality of Cancer Treatment”
Hong Kong, China, March 12, 2019
- 2019 Radiation Oncology Department Seminar, Tianjin Huanhu Hospital
“Maximizing the Efficacy of Tumor Treating Fields”
Tianjin, Hebei, China, June 14, 2019
- 2019 The 2019 Chinese Society of Neuro-Oncology Annual Meeting

Keynote Address: “Tumor Treating Fields: From Scientific Concept to Clinical Reality”
Fuzhou, Fujian, China, June 15, 2019

- 2019 The 2019 Chinese Society of Neuro-Oncology Annual Meeting
Physics Treatment Session: “Maximizing the Efficacy of Tumor Treating Fields”
Fuzhou, Fujian, China, June 15, 2019
- 2019 Live Webcast: Taiwan Society for Neuro-Oncology & Chang Gung Memorial Hospital
“Tumor Treating Fields (TTFields): From Scientific Concept to Clinical Reality”
Taipei, Taiwan, September 4, 2019
- 2020 Live Webcast: Taiwan National University Hospital
“Tumor Treating Fields (TTFields): From Scientific Concept to Clinical Reality”
Taipei, Taiwan, February 6, 2020
- 2020 Live International Webcast: Musella Foundation for Brain Tumor Research & Information
“Brain Tumor Patients and the COVID-19 Crisis”
Hewlett, New York, April 5, 2020
- 2020 Live International Webcast: Musella Foundation for Brain Tumor Research & Information
“Tumor Treating Fields Therapy: Progress in the Past Decade”
Hewlett, New York, April 12, 2020
- 2020 Live International Teleconference: Brain Tumor Foundation & CancerCare Teleconference
“Update on Glioblastoma in Adults”
CancerCare
New York, New York, April 23, 2020
- 2021 Live International Webcast: Visiting Professor Presentation
Sumitomo Dainippon Pharma Oncology / Boston Biomedical
“Clinical Application of Tumor Treating Fields & Management of Glioblastoma Patients”
Boston, Massachusetts, March 5, 2021
- 2021 Live International Teleconference: Brain Tumor Foundation & CancerCare Teleconference
“Update on Glioblastoma in Adults”
CancerCare
New York, New York, March 18, 2021
- 2021 Live International Webcast: Visiting Professor Presentation
Sumitomo Dainippon Pharma Oncology / Boston Biomedical
“Scientific Basis of Tumor Treating Fields & Management of Glioblastoma Patients”
Boston, Massachusetts, March 19, 2021
- 2021 Live International Webcast: Scientific Session Co-Chair
2021 Brain and Human Body Modeling Conference
Sesion IV: Modeling Tumor Treating Fields (Intermediate Frequency Band) in the Brain
Sponsored by National Insitute of Mental Health
Martinos Center for Biomedical Imaging, Massachusetts General Hospital

Boston, Massachusetts, August 20, 2021

2021 Pre-Recorded International Webcast: Invited Speaker
Chinese Society of Neuro-Oncology Annual Meeting 2021
Tumor Treating Fields: Mechanisms of Action and Clinical Application
Providence, Rhode Island, October 22, 2021

Report of Clinical Activities and Innovations

Current Licensure and Certification

Licensure:

1997 State of Massachusetts, Active

Board Certification:

1990 Diplomate, National Board of Medical Examiners

1995 Diplomate, American Board of Psychiatry and Neurology

2005 Diplomate, American Board of Psychiatry and Neurology (First Recertification)

2015 Diplomate, American Board of Psychiatry and Neurology (Second Recertification)

Practice Activities

1997 –	Attending Physician	Beth Israel Deaconess Medical Center
1998 – 2017	Consultant Neurologist	South Cove Community Health Center
2008 – 2010	Consultant Neurologist	Quincy Center Primary Care, P.C.

Clinical Innovations

2011 NovoTTF-100A for Recurrent Glioblastoma: BIDMC is the first site certified and treated such patients in the United States.

Report of Technological and Other Scientific Innovations

2012 Provisional Patent: Hamilton Brook Smith Reynolds Docket #1440.2075-000
“Metabolomics of Human Biological Fluids Identify Signatures of Malignant Glioma”
Eric T Wong and John M Asara

- 2013 Provisional Patent: PCT/US2014/067305
 “Metastatic Melanoma Biomarkers”
 November 25, 2014
 Kenneth D Swanson and **Eric T Wong**
- 2016 Provisional Patent: PCT/US2019/0314631
 “System and Methods for Cancer Treatment using Alternating Electric Fields”
 September 23, 2016
 Eric T Wong and Edwin Lok

Report of Education of Patients and Service to the Community

Activities

- 1998 – 2011 Celebration for Life: A yearly celebration event for cancer survivors and patient information session.
- 2007 – A Reason To Ride: A yearly event to inspire brain tumor patients.
- 2008 Heart and Brain Health: A Lecture at the Multicultural Coalition on Aging
 Sponsored by Tufts Health Plan
- 2010 Navigating Through Insurance Companies with Cancer or Catastrophic Illness
 Sponsored by the Chinese Center of Long Island
- 2013 Teleconference on Update on Glioblastoma
 Sponsored by CancerCare
 May 23, 2013
- 2013 Committee Chair, Research Poster Competition Award
 28th Annual Meeting of the Massachusetts Society of Clinical Oncologists
 Dedham, Massachusetts, November 7, 2013
- 2014 Committee Chair, Research Poster Competition Award
 29th Annual Meeting of the Massachusetts Society of Clinical Oncologists
 Dedham, Massachusetts, November 6, 2014
- 2015 Committee Chair, Research Poster Competition Award
 30th Annual Meeting of the Massachusetts Society of Clinical Oncologists
 Dedham, Massachusetts, November 12, 2015
- 2016 Teleconference on Update on Glioblastoma
 Sponsored by CancerCare
 March 24, 2016
- 2016 Committee Chair, Research Poster Competition Award
 31st Annual Meeting of the Massachusetts Society of Clinical Oncologists
 Dedham, Massachusetts, November 3, 2016

- 2017 Teleconference on Update on Glioblastoma
Sponsored by CancerCare
March 23, 2017
- 2017 Committee Chair, Research Poster Competition Award
32nd Annual Meeting of the Massachusetts Society of Clinical Oncologists
Dedham, Massachusetts, November 9, 2017
- 2018 Teleconference on Update on Glioblastoma
Sponsored by CancerCare
January 11, 2018
- 2018 Brain Tumor Awareness Webnair
Musella Foundation
May 27, 2018
- 2018 Committee Chair, Research Poster Competition Award
33rd Annual Meeting of the Massachusetts Society of Clinical Oncologists
Needham, Massachusetts, November 8, 2018
- 2019 Teleconference on Update on Glioblastoma in Adults
Sponsored by CancerCare
February 21, 2019
- 2019 Committee Chair, Research Poster Competition Award
34th Annual Meeting of the Massachusetts Society of Clinical Oncologists
Newton, Massachusetts, November 14, 2019
- 2020 Brain Tumor Awareness Webnair
“Brain Tumor Patients and the COVID-19 Crisis”
Musella Foundation
April 5, 2020
- 2020 Brain Tumor Awareness Webnair
“Tumor Treating Fields Therapy: Progress in the Past Decade”
Musella Foundation
April 12, 2020
- 2020 Teleconference on Update on Glioblastoma in Adults
Sponsored by CancerCare
April 23, 2020
- 2021 Teleconference on Update on Glioblastoma in Adults
Sponsored by CancerCare
April 23, 2021

2021 Testimony to Health Care Financing Committee, Commonwealth of Massachusetts
H.1311 & S.756 Bills: “An Act Relative to Fail First and Patient Safety”
July 12, 2021

Report of Scholarship

Publications

Peer reviewed publications in print or other media

Original Contributions:

1. Wasserman AJ, Doillon CJ, Glasgold AI, Kato YP, Christiansen D, Rizvi A, **Wong E**, Goldstein J, Silver FH. Clinical application of scanning electron microscopy in analysis of collagenous biomaterials. *Scanning Microscopy* 1988;2:1635-1646.
2. Vahdat L, **Wong ET**, Wile MJ, Rosenblum M, Foley KM, Warrell RP. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. *Blood* 1994;84:3429-3434.
3. **Wong ET**, Holstad SG, Mennerick SJ, Hong SE, Zorumski CF, Isenberg KE. Pharmacological and physiological properties of a putative ganglionic nicotinic receptor, $\alpha 3\beta 4$, expressed in transfected eucaryotic cells. *Molecular Brain Research* 1995;28:101-109.
4. **Wong ET**, Holstad SG, Mennerick SJ, Hong SE, Zorumski CF, Isenberg KE. Analysis of recombinant neuronal nicotinic acetylcholine receptors by transient expression in eucaryotic cells in vitro. *Neuroscience Protocols* 1996;20:1-11.
5. **Wong ET**, Portlock CS, O'Brien JP, DeAngelis LM. Chemosensitive epidural spinal cord disease in non-Hodgkin's lymphoma. *Neurology* 1996;46:1543-1547.
6. **Wong ET**, Jackson EF, Hess KR, Schomer DF, Hazle JD, Kyritsis AP, Jaeckle KA, Yung WKS, Levin VA, Leeds NE. Correlation between dynamic MRI and outcome in patients with malignant gliomas. *Neurology* 1998;50:777-781.
7. Hess KT, **Wong ET**, Jaeckle KA, Kyritsis AP, Levin VA, Prados MD, Yung WKA. Response and progression in recurrent malignant glioma. *Neuro-Oncology* 1999;1:282-288.
8. **Wong ET**, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WKA. Outcomes and prognostic factors in recurrent glioma patients enrolled in phase II clinical trials. *Journal of Clinical Oncology* 1999;17:2572-2578.
9. Jaeckle KA, Phuphanich S, van den Bent MJ, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day SJ, Akerley W, Allen J, Baidas S, Gertler SZ, Greenberg HS, LaFollette S, Lesser G, Mason W, Recht L, **Wong E**, Chamberlain MC, Cohn A, Glantz MJ, Gutheil JC, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell SB. Intrathecal

treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. *British Journal of Cancer* 2001;84:157-163.

10. Jaeckle KA, Batchelor T, O'Day SJ, Phuphanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, **Wong E**, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen, Howell SB. An open label trial of sustained-release cytarabine (DepoCyt™) for the intrathecal treatment of solid tumor neoplastic meningitis. *Journal of Neuro-Oncology* 2002;57:231-239.
11. **Wong ET**, Tishler R, Barron L, Wu, JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. *Cancer* 2004;101:139-145.
12. **Wong ET**. Monoclonal antibody therapy for central nervous system lymphomas: an emerging treatment paradigm. *Expert Opinion on Pharmacotherapy* 2005;6:1107-1114.
13. Ramnarain DB, Park S, Lee DY, Hatanpaa KJ, Scoggin SO, Out H, Libermann TA, Raisanen JM, Ashfaq R, **Wong ET**, Wu J, Elliott R, Habib AA. Differential gene expression analysis reveals generation of an autocrine loop by a mutant EGFR in glioma cells. *Cancer Research* 2006;66:867-874.
14. **Wong ET**, Lee D, Tam A, Wu JK. Activated matrix metalloproteinase-9 in cerebrospinal fluid correlates with disease activity in central nervous system lymphomas. *Clinical Lymphoma and Myeloma* 2007;7:305-308.
15. **Wong ET**, Brem S. Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. *Journal of the National Comprehensive Cancer Network* 2008;6:515-522.
16. Lu XQ, Shanmugham LN, Mahadevan A, Nedeia E, Stevenson MA, Kaplan I, **Wong ET**, LaRosa S, Wang F, and Berman S. Organ deformation and dose coverage in robotic respiratory tracking treatment. *International Journal of Radiation Oncology Biology Physics* 2008;71:281-289.
17. **Wong ET**, Alsop D, Lee D, Tam A, Barron L, Bloom J, Gautam S, Wu JK. Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomas. *Cerebrospinal Fluid Research* 2008;5:e1.
18. Park S, Zhao D, Hatanpaa KJ, Mickey BE, Saha D, Boothman DA, Story MD, **Wong ET**, Burma S, Georgescu MM, Rangnekar V, Chauncey SS, Habib AA. RIP1 activates PI3K-Akt via a dual mechanism involving NF-kappaB mediated inhibition of the mTOR-S6K-IRS1 negative feedback loop and downregulation of PTEN. *Cancer Research* 2009;69:4107-4111.
19. Drappatz J, **Wong ET**, Schiff D, Kesari S, Batchelor TT, Ramakrishna N, Weiss S, Doherty L, LaFrankie D, Ciampa A, Smith ST, Zimmerman J, Ostrowsky L, David K, Norden A, Black P, Wen PY. A pilot safety study of lenalidomide and radiation therapy for patients with newly diagnosed glioblastoma multiforme. *International Journal of Radiation Oncology Biology Physics* 2009;73:222-227.
20. Drappatz J, Norden AD, **Wong ET**, Doherty LM, LaFrankie DC, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Schiff D, Batchelor TT, Lassman A, Ligon KL, Young G, Muzikansky A, Weiss

- S, Wen PY. Phase I study of vandetanib with radiation therapy and temozolomide for newly-diagnosed glioblastoma. *International Journal of Radiation Oncology Biology Physics* 2010;78:85-90.
21. Wen PY, Macdonald DR, Reardon DA, Cloughesy TM, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, **Wong ET**, Chamberlain M, Stupp R, Lamborn KR, Vogelbaum M, Van den Bent MJ, Chang SM. Proposal for an updated response assessment criteria for high-grade gliomas. Response assessment in Neuro-Oncology (RANO) working group. *Journal of Clinical Oncology* 2010;28:1963-1972.
 22. Mahadevan A, Floyd S, **Wong E**, Jeyapalan S, Groff M, Kasper E. Stereotactic body radiotherapy reirradiation for recurrent epidural spinal metastases. *International Journal of Radiation Oncology Biology Physics* 2011;81:1500-1505. (doi: 10.1016/j.ijrobp.2010.08.012)
 23. Wang F, Bhat K, Doucette M, Gu Y, Law B, Liu X, **Wong ET**, Kang JX, Hsieh TC, Qian SY, Wu E. Docosahexenoic acid (DHA) sensitizes brain tumor cells to etoposide-induced apoptosis. *Current Molecular Medicine* 2011;6:503-511.
 24. Lun M, Gautam S, Wu E, **Wong ET**. The natural history of extracranial metastasis from glioblastoma multiforme. *Journal of Neuro-Oncology* 2011;105:261-273.
 25. Mahadevan A, Floyd S, **Wong E**, Chen C, Kasper E. Clinical outcome after hypofractionated stereotactic radiotherapy (HSRT) for benign skull base tumors. *Computer Aided Surgery* 2011;16:112-120. (doi: 10.3109/10929088.2011.565160)
 26. **Wong ET**, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevacizumab for recurrent glioblastoma multiforme: a meta-analysis. *Journal of National Comprehensive Cancer Network* 2011;9:403-407.
 27. Lehtinen MK, Zappaterra MW, Chen X, Yang YJ, Maynard T, Lun M, Peters A, Ye P, D'Ercole AJ, **Wong ET**, LaMantia AS, Walsh CA. Age dependent regulation of neural progenitor cells by the cerebrospinal fluid (CSF) proteome. *Neuron* 2011;69:893-905.
 28. Wang CC, Floyd SR, Chang CH, Warnke PC, Chio CC, Kasper EM, Mahadevan A, **Wong ET**, Chen CC. Cyberknife hypofractionated stereotactic radiosurgery (HSRS) of resection cavity after excision of large cerebral metastasis: Efficacy and safety of an 800 cGy x 3 daily fractions regimen. *Journal of Neuro-Oncology* 2012;106:601-610. (doi: 10.1007/s11060-011-0697-z)
 29. Yu A, Teich DL, Moonis G, **Wong ET**. Superior semicircular canal dehiscence in East Asian women with osteoporosis. *BMC Ear Nose and Throat Disorders* 2012;12:8. (doi: 10.1186/1472-6815-12-8)
 30. Locasale JW, Melman T, Song S, Yang X, Swanson KD, Cantley LC, **Wong ET***, Asara JM*. Metabolomics of patient cerebrospinal fluid identifies signatures of malignant gliomas. *Molecular Cellular Proteomics* 2012;11:M111.014688. *Contributed equally (doi: 10.1074/mcp.M111.014688)
 31. Lu R, Wu C, Guo L, Liu Y, Mo W, Wang H, **Wong ET**, Yu M. The roles of brevicin in gliomas: promoting tumor cell motility in vitro and in vivo. *BioMedCentral Cancer* 2012;12:607 (doi:

10.1186/1471-2407-12-607)

32. Stupp R, **Wong ET**, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Lieberman F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honorat J, Sloan A, Malkin M, Landolfi JC, payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomized phase III trial of a novel treatment modality. *European Journal of Cancer* 2012;48:2192-2202. (doi: 10.1016/j.ejca.2012.04.011)
33. Floyd SR, Kasper EM, Uhlmann EJ, Fonkem E, **Wong ET**, Mahadevan A. Hypofractionated radiotherapy and stereotactic boost with concurrent and adjuvant temozolomide for glioblastoma in good performance status elderly patients – early result of a phase II trial. *Frontiers in Oncology* 2012;2:122. (doi: 10.3389/fonc.2012.00122)
34. Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, LoGuidice L, Soto H, Garrett M, Zhu LD, Sivaraman S, Chen C, **Wong ET**, Carter BS, Hochberg FH, Breakefield XO, Skog J. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. *Molecular Therapy Nucleic Acids* 2013;2:e109. (doi: 10.1038/mtna.2013.28)
35. Drappatz J, Brenner A, **Wong ET**, Eichler A, Schiff D, Groves MD, Mikkelsen T, Rosenfeld S, Sarantopoulos J, Meyers CA, Fielding RM, Elian K, Wang X, Lawrence B, Shing M, Kelsey S, Castaigne JP, Wen PY. Phase I study of GRN1005 in recurrent malignant glioma. *Clinical Cancer Research* 2013;19:1567-1576. (doi: 10.1158/1078-0432.CCR-12-2481)
36. Recht L, Mechtler LL, **Wong ET**, Rodda B, O'Connor PC. Steroid sparing effect of corticorelin acetate (CrA) in peritumoral cerebral edema is associated with improvement in steroid induced myopathy. *Journal of Clinical Oncology* 2013;31:1182-1187. (doi: 10.1200/JCO.2012.43.9455)
37. Kanner AA*, **Wong ET***, Villano J, Ram Z. Post hoc analysis of the ITT population in the phase III comparison of NovoTTF-100A versus Best Physician's Choice chemotherapy. *Seminars in Oncology* 2014;41 (Supplement 6):S25-S34. *Contributed equally (doi: 10.1053/j.seminoncol.2014.09.008)
38. Josef Vymazal, **Wong ET**. The response pattern of recurrent glioblastomas treated with tumor treating fields. *Seminars in Oncology* 2014;41 (Supplement 6):S14-S24. (doi: 10.1053/j.seminoncol.2014.09.009).
39. Fonkem E, Robison D, Lok E, Gautam S, **Wong ET**. The natural history of intravascular lymphomatosis. *Cancer Medicine* 2014;3:1010-1024 (doi: 10.1002/cam4.269).
40. Scheidegger R, **Wong ET**, Alsop DC. Contributors to contrast between glioma and brain tissue in chemical exchange saturation transfer sensitive imaging at 3 Tesla. *NeuroImage* 2014;99:256-268 (doi: 10.1016/j.neuroimage.2014.05.036).
41. Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davis AM, **Wong ET**. Characterization and management of dermatologic adverse events with the

NovoTTFTM-100A system, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma (rGB). *Seminars in Oncology* 2014;41:S1-S14. (doi: dx.doi.org/10.1053/j.seminoncol.2014.03.011).

42. **Wong ET**, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, Taillibert S, Ram Z, Villano JL. Response assessment of NovoTTF-100A versus Best Physician's Choice chemotherapy in recurrent glioblastoma. *Cancer Medicine* 2014;3:592-602. (doi: 10.1002/cam4.210)
43. Lok E, Chung AS, Swanson KD, **Wong ET**. Melanoma brain metastasis globally reconfigures chemokine and cytokine profiles in patient cerebrospinal fluid. *Melanoma Research* 2014;24:120-130. (doi: 10.1097/CMR.000000000000045)
44. Mahadevan A, Sampson C, LaRosa S, Floyd SR, **Wong ET**, Uhlmann EJ, Sengupta S, Kasper EM. Dosimetric analysis of the alopecia preventing effect of hippocampus sparing whole brain radiation therapy. *Radiation Oncology* 2015;10:e245.
45. **Wong ET**, Lok E, Gautam S, Swanson KD. Dexamethasone exerts profound interference on treatment efficacy for recurrent glioblastoma. *British Journal of Cancer* 2015;113:232-241. (doi: 10.1038/bjc.2015.238)
46. Lai GY, Mahadevan A, Carter R, Kasper E, Warnke PC, **Wong ET**, Nigim F, Chen CC. Diagnostic Accuracy of PET, SPECT, and ASL in differentiating tumor recurrence from necrosis in cerebral metastasis post-stereotactic radiosurgery. *AJNR American Journal of Neuroradiology* 2015;36:2250-2255.
47. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, **Wong ET**, Huberman MS, Costa DB. Brain metastases are frequent in patients with EGFR-mutated or ALK-rearranged lung cancers. *Lung Cancer* 2015;88:108-111. (doi: dx.doi.org/10.1016/j.lungcan.2015.01.020)
48. Lee EQ, Kaley TJ, Duda DG, Schiff D, Lassman AB, **Wong ET**, Mikkelsen T, Purow BW, Muzikansky AM, Ancukiewicz M, Hughes J, Ramkissoon S, Drappatz J, Norden AD, Beroukhi R, Weiss SE, Alexander BM, McCluskey CS, Gerard M, Smith KH, Jain R, Batchelor TT, Ligon K, Wen PY. A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly-diagnosed glioblastoma patients. *Clinical Cancer Research* 2015;21:3610-3618. (doi: 10.1158/1078-0432.CCR-14-3220)
49. Gera N, Yang A, Holtzman TS, Lee SX, **Wong ET**, Swanson KD. Tumor treating fields perturbs the localization of Septins and cause aberrant mitotic exit. *PLOS ONE* 2015;10:e0125269. (doi: 10.1371/journal.pone.0125269)
50. **Wong ET**, Lok E, Swanson KD. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation. *Cancer Medicine* 2015;4:383-391 (doi: 10.1002/cam4.421).
51. Ippen F, Mahadevan A, **Wong ET**, Uhlmann E, Sengupta S, Kasper E. Stereotactic radiosurgery for renal cancer brain metastasis: Prognostic factors and the role of whole brain radiation and surgical resection. *Journal of Oncology* 2015;2015:636918.

52. Christ S, Mahadevan A, Floyd S, Lam F, Chen CC, **Wong ET**, Kasper E. Stereotactic radiosurgery for brain metastases from malignant melanoma. *Surgical Neurology International* 2015;6:S355-S365.
53. Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, **Wong ET**, Drappatz J, Lesser GJ, Haider S, Beroukhir R, Lee EQ, Doherty L, LaFrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY. Phase II study of monthly parsireotide LAR (SOM230C) for recurrent or progressive meningioma. *Neurology* 2015;84:280-286. (doi: 10.1212/WNL.0000000000001153)
54. Wang F, Remke M, Bhat K, **Wong ET**, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh TC, O'Rourke S, Wu L, Li DW, Hawkins C, Kohane IS, Wu JM, Wu M, Taylor MD, Wu E. A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. *Oncotarget* 2015;6:2709-2724 (PMID: 25576913).
55. Fonkem E, Dayawansa S, Bricker PC, Kirmani B, Thawani N, Stroberg E, Lok E, Singel S, **Wong ET**, Huang JH. Neurologic presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients. *BMC Neurology* 2016;16:e9. (doi: 10.1186/s12883-015-0509-8)
56. Lee EQ, Muzikansky A, Drappatz J, Kesari S, **Wong ET**, Fadul CE, Reardon DA, Norden AD, Nayak L, Rinne ML, Alexander BM, Arvold ND, Doherty L, Stefanik J, LaFrankie D, Ruland SF, Pulverenti J, Smith KH, Gaffey SC, Hammond S, Wen PY. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. *Neuro-Oncology* 2016;18:849-854.
57. Timmons JJ, Cohessy S, **Wong ET**. Injection of syngeneic murine melanoma cells to determine their metastatic potentials in the lungs. *Journal of Visualized Experiments* 2016;111:e54039.
58. **Wong ET**, Timmons J, Callahan A, O'Loughlin L, Giarrusso B, Alsop DC. Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas. *BMC Cancer* 2016;16:e914.
59. Zhao L, Dai W, Soman S, Hackney DB, **Wong E**, Robson PM, Alsop DC. Using anatomic magnetic resonance image information to enhance visualization and Interpretation of functional images: A comparison of methods applied to clinical arterial spin labeling images. *IEEE Transactions on Medical Imaging* 2017;36:487-496. (doi: 10.1109/TMI.2016.2615567)
60. Kasper E, Ippen F, **Wong E**, Uhlmann E, Floyd S, Mahadevan A. Stereotactic radiosurgery for brain metastasis from gynecological malignancies. *Oncology Letters* 2017;13: 1525-1528.
61. Lok E, San P, Hua V, Phung M, **Wong ET**. Analysis of physical characteristics of tumor treating fields for human glioblastoma. *Cancer Medicine* 2017;6:1286-1300.
62. Timmons JJ, Lok E, San P, Bui K, **Wong ET**. End-to-end workflow for finite element analysis of Tumor Treating Fields in glioblastoma. *Physics in Medicine & Biology* 2017;62:8264-8282.
63. Lukas RV, Rodon J, Becker K, **Wong ET**, Shih K, Touat M, Fassò M, Osborne S, Molinero L, O'Hear C, Grossman W, Baehring J. Clinical activity and safety of atezolizumab in patients with

recurrent glioblastoma. *Journal of Neuro-Oncology* 2018;140:317-328. (doi: 10.1007/s11060-018-2955-9).

64. Timmons JJ, Preto J, Tuszynski JA, **Wong ET**. Tubulin's response to external electric fields by molecular dynamics simulations. *PLOS ONE* 2018;13(9):e0202141.
65. Coulter ME, Dorobantu CM, Lodewijk GA, Delalande F, Cianferani S, Ganesh V, Smith R, Lim ET, C. Xu S, Pang S, **Wong ET**, Lidov HGW, Calicchio ML, Yang E, Gonzalez DM, Schlaeger T, Mochida G, Hess H, Lee WCA, Lehtinen MK, Kirchhausen T, Haussler D, Jacobs FMJ, Gaudin R, Walsh CA. The ESCRT-III protein CHMP1A mediates secretion of sonic hedgehog on ART subtype of extracellular vesicles. *Cell Report* 2018;24(4):973-986.
66. Wang F, Zheng Z, Guan J, Qi D, Zhou S, Shen X, Wang F, Wenkert D, Kirmani B, Solouki T, Fonkem E, **Wong ET**, Huang J, Wu E. Identification of a panel of genes as a prognostic biomarker for glioblastoma. *EBioMedicine* 2018;37:68-77. (doi: 10.1016/j.ebiom.2018.10.024)
67. Wang F, Zhou S, Qi D, Xiang SH, **Wong ET**, Wang X, Fonkem E, Hsieh TC, Yang J, Kirmani B, Shabb J, Wu J, Wu M, Huang J, Yu WH, Wu E. Nucleolin is a functional binding protein for salinomycin in neuroblastoma stem cells. *Journal of the American Chemical Society* 2019;141(8):3613-3622. (doi: 10.1021/jacs.8b12872)
68. Martucci MG, McIlduff CE, Shin C, Gutierrez JV, Nam JY, Greenstein P, Phillips K, Uhlmann E, **Wong ET**, Rutkove SB. Quantitative ultrasound detects corticosteroid-induced muscle changes. *Clinical Neurophysiology* 2019;130(8):1460-1464. (doi: 10.1016/j.clinph.2019.04.709)
69. Lok E, San P, Liang O, White V, **Wong ET**. Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. *Journal of Neuro-Oncology* 2020;147:125-133.
70. Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, **Wong ET**, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klotfas LK, Bertalan MS, Betensky RA, Curry WT, Borger DR, Giorgio DH, Balaj L, Kitchen RR, Chakraborty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Exploring predictors of response to dacomitinib in *EGFR*-amplified recurrent glioblastoma. *Journal of Clinical Oncology Precision Oncology* 2020;4:593-613.
71. Dietrich J, Versmee L, Drappatz J, Eichler A, Nayak L, Norden A, **Wong ET**, Pisapia M, Jones SA, Gordon A, Chabner B, Hochberg F, Batchelor TT. Alimta (Pemetrexed) in recurrent or progressive primary central nervous system lymphoma: A phase I multicenter clinical trial. *Oncologist* 2020;25:1-10.
72. Ho GKW, Uhlmann EN, **Wong ET**, Uhlmann EJ. Leukopenia is a biomarker for correct temozolomide dosing and overall survival for patients with glioblastoma. *Molecular and Clinical Oncology* 2020;13(6):80.
73. Gatson NTN, Barnholtz-Sloan J, Drappatz J, Henriksson R, Hottinger AF, Hinoul P, Kruchko C, Puduvalli VK, Tran DD, **Wong ET**, Glas M. Tumor Treating Fields for glioblastoma therapy during the COVID-19 pandemic. *Frontiers in Oncology* 2021;11:679702. (doi: 10.3389/fonc.2021.679702)

74. Lok E, San P, White V, Liang O, Widick PC, Reddy SP, **Wong ET**. Tumor treating fields for ovarian carcinoma: a modeling study. *Advances in Radiation Oncology* 2021;16(4):100716. (doi: 10.1016/j.adro.2021.100716)
75. Mikic N, Poulsen FR, Kristoffersen KB, Laursen RJ, Guldberg TL, Skjøth-Rasmussen J, **Wong ET**, Møller S, Dahlrot RH, Sørensen JCH, Korshøj AR. Study protocol for OptimalTTF-2: Enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma. A phase 2, multi-center, randomized, prospective, interventional trial. *BMC Cancer* 2021. (in press)
76. Jang A, Petrova B, Culhane AJ, Shipley FB, Cheong TC, Chiarle R, **Wong ET**, Kanarek N, Lehtinen MK. Gene-therapy enhances CSF's anti-oxidative activity to mitigate chemotherapy side effects. *Science* 2021. (submitted)

Reviews:

1. **Wong ET**, Wu JK, Hariharan S. Clinical presentation and diagnosis of brain tumors. In: *UpToDate*, Rose BD (Ed.), *UpToDate*, Wellesley, MA 2000.
2. **Wong ET**, Joseph JJ, Tishler RK, Wu JK. Hemangioblastoma. In: *UpToDate*, Rose BD (Ed.), *UpToDate*, Wellesley, MA 2002.
3. Friedberg MH, **Wong ET**, Wu JK. Management of brain metastases in melanoma. In: *UpToDate*, Rose BD (Ed.), *UpToDate*, Wellesley, MA 2002.
4. **Wong ET**. The treatment of brain metastases in the SCLC patient. In *Current Perspective on the Treatment of Small Cell Lung Cancer*. *Oncology Journal Forum* 2003;9:1-7.
5. **Wong ET**, Berkenblit A. The role of topotecan in the treatment of brain metastases. *The Oncologist* 2004;9:68-79.
6. **Wong ET**. Management of central nervous system lymphomas using monoclonal antibodies: Challenges and Opportunities. *Clinical Cancer Research* 2005;11:7151s-7157s.
7. **Wong ET**, Linendoll N. Treatment advances for glioblastoma: Tumor markers and targeted treatments. *Applied Neurology* 2007;3:18-22.
8. Sengupta S, Pedersen NP, Davis JE, Rojas R, Reddy H, Kasper E, Greenstein P, **Wong ET**. Illusion of stroke: Intravascular lymphomatosis. *Reviews in Neurological Diseases* 2011;8:e107-e113.
9. Fonkem E, Uhlmann EJ, Floyd SR, Mahadevan A, Kasper E, Eton O, **Wong ET**. Melanoma brain metastasis: overview of current management and emerging targeted therapies. *Expert Review of Neurotherapeutics* 2012;12:1207-1215. (doi:10.1586/ern.12.111)
10. Fonkem E, **Wong ET**. NovoTTF-100A: a new treatment modality or recurrent glioblastoma. *Expert review of Neurotherapeutics* 2012;12:895-899. (doi:10.1586/ern.12.80)
11. Gutin PH, **Wong ET**. Noninvasive application of alternating electric fields in glioblastoma: a fourth

cancer treatment modality. ASCO 2012 Meeting Education Session, Central Nervous System Tumors

(<http://meetinglibrary.asco.org/sites/meetinglibrary.asco.org/files/Educational%20Book/PDF%20Files/2012/zds00112000126.pdf>)

12. Zhu JJ, **Wong ET**. Personalized medicine for glioblastoma: current challenges and future opportunities. *Current Molecular Medicine* 2013;13:358-367.
13. Butowski N, **Wong ET**, Mehta MP, Wilson LK. A roundtable discussion on the clinical challenges and options for the treatment of glioblastoma: Introducing a novel modality, TTFIELDS. *Seminars in Oncology* 2013;40:S2-4.
14. Zhou S, Wang F, **Wong ET**, Fonkem E, Hsieh TC, Wu JM, Wu E. Salinomycin: a novel anti-cancer agent with known anti-coccidial activities. *Current Medicinal Chemistry* 2013; 20:4095-4101.
15. McDuff SGR, Taich ZJ, Lawson JD, Sanghvi P, **Wong ET**, Barker FG, Hochberg FH, Loeffler JS, Warnke PC, Murphy KT, Mundt AJ, Carter BS, McDonald CR, Clark C Chen. Neurocognitive assessment following whole brain radiation therapy and radiosurgery or patients with cerebral metastases. *Journal of Neurology Neurosurgery & Psychiatry* 2013;84:1384-1391.
16. Invited Review: Lok E, Swanson KD, **Wong ET**. Tumor treating fields therapy for glioblastoma: physics and clinical practice considerations. *Expert Review of Medical Devices* 2015;12: 717-726. (dx.doi.org/10.1586/17434440.2015.1086641).
17. Invited Review: **Wong ET**, Lok E, Swanson KD. An evidence based review of alternating electric fields therapy for malignant gliomas. *Current Treatment Options in Oncology* 2015;16:40 (doi: 10.1007/s11864-015-0353-5).
18. **Wong ET**, Toms SA, Ahluwalia MS. Clinical Roundtable Monograph: Technological Advances in the Treatment of Cancer: Combining Modalities to Optimize Outcomes. *Clinical Advances in Hematology & Oncology* 2015;13(Supplement 11):1-18.
19. Invited Review: Swanson KD, Lok E, **Wong ET**. An overview of alternating electric fields therapy (NovoTTF Therapy) for the treatment of malignant glioma. *Current Neurology and Neuroscience Report* 2016;16:8. (doi: 10.1008/s11910-015-0606-5)
20. Lukas RV, Ratermann KL, **Wong ET**, Villano JL. Skin toxicities associated with tumor treating fields: case based review. *Journal of Neuro-Oncology* 2017;135:593-599. doi: 10.1007/s11060-017-2612-8 (epub ahead of print).
21. Invited Review: **Wong ET**, Lok E, Swanson KD. Alternating electric fields therapy for malignant gliomas: from bench observation to clinical reality. In Chernov MF, Muragaki Y, Kesari S, McCutcheon IE (eds.): *Intracranial Gliomas Part III – Innovative Treatment Modalities*. *Progress in Neurosurgery* 2018;32:180-195.
22. Timmons JJ, Zhang K, Fong J, Lok E, Swanson KD, Gautam S, **Wong ET**. Literature review of spinal cord glioblastoma. *American Journal of Clinical Oncology* 2018;41:1281-1287. (doi:

10.1097/COC.0000000000000434)

23. Riley M, San P, Lok E, Swanson KD, **Wong ET**. The clinical application of Tumor Treating Fields therapy in glioblastoma. *Journal of Visualized Experiments* 2019;146:e58937. (doi:10.3791/58937)
24. Invited Review: **Wong ET**. Tumor treating fields therapy for glioblastoma: an update. *Glioma* 2019;2:61-67.
25. Invited Review: Berger T, **Wong ET**. Tumor Treating Fields in neuro-oncology: Integration of alternating electric fields therapy into promising treatment strategies. *Chinese Clinical Oncology* 2021;10(4):36. doi:10.21037/cco.2020.02.04. [Epub ahead of print]

Case Reports:

1. **Wong ET**, Malkin MG, Patt RB. Pain from a shunt-induced abdominal phlegmon in a cancer patient. *Primary Care & Cancer* 1996;17:22-27.
2. **Wong ET**, Ginsberg LE, Patt RB, Payne R. Radiation-induced insufficiency fracture of the sacrum may simulate metastatic prostate cancer. *Primary Care & Cancer* 1996;16:12,17.
3. **Wong ET**, Gaughan E, Gunes S, Patt RB, Hassenbusch SJ, Payne R. Palliation of intractable cancer pain by MRI-guided cingulotomy. *Clinical Journal of Pain* 1997;13:260-263.
4. **Wong ET**, O'Brien S. Leptomeningeal disease in pre-leukemic syndrome: cytogenetic abnormality versus cellular morphology. *Oncology Reports* 1998;5:493-495.
5. **Wong ET**. Recurrent cystic radiation necrosis of the brain. *Oncology Reports* 1998;5:685-687.
6. **Wong ET**, Joseph JJ. Carcinomatous leptomeningeal metastasis. *Journal of Clinical Oncology* 2000;18:2926-2927.
7. **Wong ET**, Louis DT. Case Record of the Massachusetts General Hospital: A 61-year-old man with transient quadriplegia and apnea. *New England Journal of Medicine* 2001;344:832-839.
8. Freedman SJ, Pantanowitz L, Joseph JJ, Wu J, **Wong ET**, Dezube BJ. Unusual locations for lymphomas: pineal lymphoma. *Journal of Clinical Oncology* 2001;19:2960-2963.
9. **Wong ET**, Barron L, Wu JK. Peripartum pituitary hypertrophy. *Neurology Reviews* 2005;13:9-10.
10. **Wong ET**, Liu XQ, Devulapalli J, Mahadevan A. Cyberknife radiosurgery for basal skull plasmacytoma. *Journal of Neuroimaging* 2006;16:361-363.
11. **Wong ET**. Tumor growth, angiogenesis, and invasion. *Journal of Neuro-Oncology* 2006;77:295-296.
12. **Wong ET**, Wu JK, Mahadevan A. Gefitinib and high-dose fractionated radiotherapy for

carcinomatous encephalitis from non-small cell lung cancer. *Biologics: Targets and Therapy* 2007;1:321-324.

13. **Wong ET**, Huberman M, Lu XQ, Mahadevan A. Bevacizumab reverses cerebral radiation necrosis. *Journal of Clinical Oncology* 2008;26:5649-5650.
14. Jia Y, Kraus JA, Reddy H, Groff M, **Wong ET**. Polyradiculopathies from schwannomatosis. *The Open Neuroimaging Journal* 2011;5:9-13.
15. Elzinga G, **Wong ET**. Resolution of cystic enhancement to add-on tumor treating electric fields (TTFields) for recurrent glioblastoma after incomplete response to bevacizumab. *Case Reports in Neurology* 2014;6:109-115.
16. Lok E, Hua V, **Wong ET**. Computed modeling of alternating electric fields therapy for recurrent glioblastoma. *Cancer Medicine* 2015;4:1697-1699 (doi: 10.1002/cam4.519).
17. Maragos G, Pihan G, **Wong ET**, Motiei-Langroudi R, Papavassiliou E. Nerve Root Biopsy in Intramedullary Spinal Cord Lymphoma: Technical Note and Case Report. *Interdisciplinary Neurosurgery* 2020;199:100599.
18. **Wong ET**, Moore J, Hertan L, Uhlmann EJ. Rapid progressive glioblastoma despite radiation in a patient with myelodysplastic syndrome. *Case Reports in Oncology* 2021;14:424–429.
19. Cole SM, Sarangi S, Einstein D, McMasters M, Alterman R, Bruce J, Hertan L, Shih H, **Wong ET**. Parkinsonism reversed from treatment of pineal non-germinomatous germ cell tumor. *Surgical Neurology International* 2021. http://dx.doi.org/10.25259/SNI_595_2020
20. Ho KG, Anderson MP, Uhlmann EJ, **Wong ET**. Paraneoplastic intestinal syndrome in a patient with glioblastoma. *Neurology* (submitted).

Book Chapters:

1. **Wong ET**. Back Pain. In B Furie, RJ Mayer, PA Cassileth, MB Atkins (Eds): *Clinical Practice of Hematology and Oncology: Presentation, Diagnosis, and Treatment*, W.B. Saunders, pp. 156-164, 2003.
2. **Wong ET**. Cranial Neuropathy. In B Furie, RJ Mayer, PA Cassileth, MB Atkins (Eds): *Clinical Practice of Hematology and Oncology: Presentation, Diagnosis, and Treatment*, W.B. Saunders, pp. 27-31, 2003.
3. **Wong ET**. Headache. In B Furie, RJ Mayer, PA Cassileth, MB Atkins (Eds): *Clinical Practice of Hematology and Oncology: Presentation, Diagnosis, and Treatment*, W.B. Saunders, pp. 19-22, 2003.
4. **Wong ET**. Neoplastic Meningitis. In PM Black, JS Loeffler (Eds): *Cancer of the Nervous System*, Lippincott Williams & Wilkins, pp. 683-689, 2004.

5. Brem S, **Wong ET**. Angiogenesis and Brain Tumors: Molecular Targets and Molecular Scalpels. In Winn HR (Editor): Youman's Neurosurgical Surgery, 6th Edition, Elsevier, Philadelphia, PA, Chapter 104, pp. 1151-1171; e271-e277, 2011.
6. Swanson KD, Lok E, **Wong ET**. Tumor Treating Electric Fields for Glioblastoma. In Brem S and Abdullah KG (Editors): Glioblastoma, Chapter 17, pp. 213-224, 2016.
7. Brem S, **Wong ET**, Desai A, Fan Y, Pan E. Angiogenesis and Brain Tumors: Scientific Principles, Current Therapy, and Future Directions. In Winn HR (Editor): Youman's Neurosurgical Surgery, 7th Edition, Elsevier, Philadelphia, PA, 2016.
8. Lantos J, Young RJ, Miranda PC, Wenger C, **Wong ET**. TTFIELDS Therapy: Preclinical and Clinical Data. In Newton H (Editor): Handbook of Neuro-Oncology Neuroimaging, Academic Press, Elsevier, Second Edition, San Diego, California, Chapter 25, pp. 243-256, 2016.
9. **Wong ET** (Editor). Alternating Electric Fields Therapy in Oncology: A Practical Guide to Clinical Applications of Tumor Treating Fields. Springer International Publishing AG, Switzerland, 2016.
10. Lok E, Swanson KD, **Wong ET**. Electric Field Therapy of Glioblastoma. In Iv M, Wintermark M, Massoud TF (Editor): Glioblastoma: State-of-the-Art Clinical Neuroimaging, Nova Science Publishers, Inc., Hauppauge, New York 2019.
11. Diaz Ordonez M, Young RJ, Miranda PC, Wenger C, Lantos J, **Wong ET**. TTFIELDS Therapy: Preclinical and Clinical Data. In Newton H (Editor): Handbook of Neuro-Oncology Neuroimaging, Academic Press, Elsevier, Third Edition, San Diego, California, Chapter 25 (in press).

[Non-peer reviewed scientific or medical publications/materials in print or other media](#)

Letter and Correspondence:

1. Hess KR, **Wong ET**, Yung WKA. Letter to the editor: Chemotherapy response criteria in malignant gliomas. *Neurology* 1998;50:1196-1198.
2. **Wong ET**. Reply to Letter to the Editor: "Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas". *Cancer* 2004;101:2900-2902.
3. **Wong ET**. Correspondence: Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. *Neurology* 2005;64:934.
4. **Wong ET**. Correspondence: Low-dose temozolomide does not mean low toxicity. *Neurology* 2006;67:543-544.
5. Fonkem E, Lun M, **Wong ET**. The rare phenomenon of extracranial metastasis of glioblastoma. *Journal of Clinical Oncology* 2011;29:4594-4595. (doi: 10.1200/JCO.2011.39.0187)
6. **Wong ET**, Swanson KD. Response to: Comment on "Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma". *British Journal of*

Cancer 2015;113:1633-1634. (doi: 10.1038/bjc.2015.320)

7. **Wong ET**, Swanson KD. Letter to the editor: Everolimus shortens survival of newly diagnosed glioblastoma patients. *Journal of Neuro-Oncology* 2018;140(1):179-180.

Editorial:

1. **Wong ET**, Brem S. Editorial: Taming glioblastoma: Targeting angiogenesis. *Journal of Clinical Oncology* 2007;25:4795-4796.
2. Chowdhary S, **Wong ET**. Commentary: Bevacizumab plus irinotecan for recurrent glioblastoma multiforme. *Nature Clinical Practice Neurology* 2008;4:242-243.
3. **Wong ET**, Yamaguchi N. The changing natural history of glioblastomas. *Expert Review of Neurotherapeutics* 2011;11:1343-1345.
4. **Wong ET**, Brem S. Taming glioblastoma by targeting angiogenesis: Three years later. *Journal of Clinical Oncology* 2011;29:124-126.
5. **Wong ET**, Swanson KD. Dexamethasone - friend or foe for patients with glioblastoma? *Journal of the American Medical Association Neurology* 2019;76(3):247-248. (doi: 10.1001/jamaneurol.2018.4530)

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

1. Lockshin RA, **Wong ET**. Ecdysone-induced, and subsequent cycloheximide inhibited, labial gland depolarization in *Manduca sexta*. *Journal of Cell Biology* 1981;91:211a.
2. **Wong E**, Rizvi A, Christiansen D, Dickerman D, Geller H, Silver F. Direct neurite outgrowth on collagen fibers. *Society for Neuroscience Abstracts* 1989;15:1036.
3. **Wong E**, Rizvi A, Christiansen D, Dickerman D, Hahn R, Zazanis G, Geller H, Silver F. Neurite outgrowth from rat cortical neurons on one-micron-diameter collagen fibers. *Society for Neuroscience Abstracts* 1988;14:496.
4. **Wong ET**, Mennerick S, Clifford DB, Zorumski CF, Isenberg KE. Expression of a recombinant neuronal nicotinic acetylcholine receptor in transfected HEK-293 cells. *Society for Neuroscience Abstracts* 1993;19:290.
5. Tan CTC, Guarino L, Tong WP, Wollner N, Finlay J, Meyers PA, Steinherz PG, Ghavimi F, **Wong ET**. Clinical and pharmacologic studies of 2-chlorodeoxyadenosine (2-CdA) in children with advanced hematologic malignancies and solid tumors. *Blood* 1994;84(Suppl. 1):302a.
6. **Wong ET**, Vahdat L, Tunkel RS, Wile MJ, Rosenblum M, Warrell RP, Foley KM. Severe motor weakness from high-dose 2-chlorodeoxyadenosine. *Annals of Neurology* 1994;36:293.
7. **Wong ET**, Vahdat L, Warrell RP, Nichols GL, Foley KM. Profound motor weakness from high-dose 2-chlorodeoxyadenosine. *Proceedings of the American Society of Clinical Oncologists Annual*

Meeting 1994;13:309.

8. **Wong ET**, Portlock CS, O'Brien JB, DeAngelis LM. Chemosensitive epidural spinal cord disease in non-Hodgkin's lymphoma. *Neurology* 1995;45(Suppl. 4):A192.
9. **Wong ET**, Ater JL, Hess KR, Kuttesch JF, Kyritsis AP, Gleason MJ, Levin VA, Yung WKA. Prognostic factors in low-grade astrocytic gliomas. Seventh International Symposium on Pediatric Neuro-Oncology, Washington, DC, May 15-18, 1996.
10. **Wong ET**, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WKA. Time to tumor progression as a measure of efficacy in phase II chemotherapy trials for recurrent malignant gliomas. Proceedings of American Society of Clinical Oncologists Annual Meeting 1996;15:153.
11. **Wong ET**, Yung WKA, Fueyo J, Gomez-Manzano C, Ramdas L, Ellman J, Budde R, Levin VA. Induction of apoptosis in glioma cells by a benzodiazepin-2-one. *Journal of Neuro-Oncology* 1997;35:S49.
12. Su GW, Joseph J, Tishler R, Schachter S, Wu JK, **Wong ET**. Intractible epilepsy from a ganglioglioma with oligodendroglioma dedifferentiation. Second Congress of Oceanian Epilepsy Organization, Taipei, Taiwan, November 5-8, 1998.
13. Su G, Tishler RB, Wu JK, **Wong ET**. Gemcitabine radiosensitization in glioma cells. *Neuro-Oncology* 1999;1:S117.
14. Kunschner LJ, **Wong ET**, Hess KR, Kyritsis AP, Jaeckle KA, Levin VA, Yung WKA. Recombinant interferon- β with and without 13-cis-retinoic acid in the treatment of malignant glioma. *Neuro-Oncology* 1999;1:320.
15. Hess KR, **Wong ET**, Jaeckle KA, Yung WKA. Phase II trials in recurrent malignant glioma. *Neuro-Oncology* 1999;1:315.
16. Flowers A, **Wong E**, Landolfi J, Hariharan S, Mather J, Clark E, Johnson B. Combination chemotherapy with 6-thioguanine and temozolomide may help prolong survival in patients with recurrent glioblastoma multiforme. *Neuro-Oncology* 2002;4 (Suppl 1):S32-S33.
17. **Wong ET**, Tishler R, Barron L, Wu J. Rituximab and temozolomide immunochemotherapy for central nervous system lymphoma. *Neuro-Oncology* 2003;5:358.
18. **Wong ET**, Barron L, Bloom J, Wu J. Durable Responses from Immunochemotherapy with Rituximab and Temozolomide in Patients with Central Nervous System Lymphomas. *Cancer Biotherapy & Radiopharmaceuticals* 2004;19:514.
19. Appignani B, Hackney D, **Wong E**, Duhamel G, Wu J, Marquis R, Alsop D. Arterial spin labeling perfusion imaging for the evaluation of brain tumors at 3 Tesla. Proceedings of the Twelve International Society for Magnetic Resonance Imaging in Medicine, May 15-21, 2004, Kyoto, Japan.

20. Appignani B, Alsop D, Hackney D, **Wong E**, Wu J. Arterial spin labeling perfusion imaging of brain tumors. Radiological Society of North America 2005:SSG14-05.
21. **Wong ET**, Appignani B, Wu JK, Mahadevan A, Joseph JJ, Lee D, Tam A, Bloom J, Barron L, Hackney D, Alsop D. Arterial spin labeling MRI detects early recurrence and anti-angiogenic drug effect in recurrent malignant gliomas. Proceedings of the American Society of Clinical Oncologists Annual Meeting 2005;23:132s.
22. **Wong ET**, Barron L, Bloom J, Wu JK. Durable responses from Immunochemotherapy with rituximab and temozolomide in patients with central nervous system lymphomas. Neurology 2005;64(Suppl 1):A25.
23. **Wong ET**, Alsop D, Appignani B, Mahadevan A, Lee D, Tam A, Barron L, Bloom J, Hackney D, and Wu JK. Phase I study of irinotecan, thalidomide, and doxycycline combination for recurrent malignant gliomas, with correlative 3.0-Tesla arterial spin labeling perfusion imaging and cerebrospinal fluid zymography. Seventh International Symposium on Anti-Angiogenic Agents, La Jolla, CA, February 11-13, 2005.
24. Mechtler L, Alksne J, **Wong E**, Arenson E, Recht L, Avgeropolous N, Eisenstat D, Hormigo A, Perry J, Raizer J, Shapiro W, Taylor L, Shulman M, Carr L. Interim report of the phase III open-label study of Xerecept (corticotropin acetate injection) for treatment of peritumoral brain edema in patients with primary or secondary brain tumors. Neuro-Oncology 2006;8:446-447.
25. Glantz MJ, Chamberlain MC, Batchelor T, **Wong E**, Cavalli F, Shapiro WR. Interaction between route of intra-CSF chemotherapy administration and efficacy of therapy in patients with neoplastic meningitis. Proceedings of the American Society of Clinical Oncologists Annual Meeting 2006;24:65s.
26. **Wong ET**, Lu XQ, Devulapalli J, Mahadevan A. Frameless Cyberknife radiosurgery for basal skull plasmacytoma. Proceedings of the American Society of Clinical Oncologists Annual Meeting 2006;24:595s.
27. **Wong ET**, Appignani B, Alsop D, Hackney D, Joseph J, Kasper E, Papavassiliou E. Perfusion-guided brain biopsy for gliomatosis cerebri. Eighth International Symposium on Anti-Angiogenic Agents, La Jolla, CA, February 3-5, 2006.
28. **Wong ET**. Unusual large cell transformation of CNS chronic lymphocytic leukemia. Non-Hodgkin's Lymphoma Tumor Board, Massachusetts Society of Clinical Oncologists, Dedham, MA, January 12, 2006.
29. Recht L, Mechtler L, Alksne J, Arenson E, Paleologos N, Avgeropoulos N, Hormigo A, Perry J, Raizer J, Robins I, **Wong E**, Shulman M, Carr L. Long-term safety and steroid-sparing potential of corticotropin acetate injection for treatment of peritumoral brain edema: Third interim report of an open-label study as part of a phase III program. Neuro-Oncology 2007;9:570.
30. Yu M, Song S, Nguyen S, Jeyapalan S, Groves M, Swanson K, Gautam S, **Wong ET**. Vascular endothelial growth factor (VEGF) and matrix metalloprotease (MMP) cerebrospinal fluid (CSF) biomarkers in lymphomatous meningitis. Neuro-Oncology 2007;9:548.

31. Yu M, Song S, Nguyen S, Gu H, **Wong ET**. Cerebrospinal fluid (CSF) O6-methylguanine-methyltransferase (MGMT) from patients with glioblastoma multiforme. *Neuro-Oncology* 2007;9:549.
32. Drappatz J, **Wong ET**, Kesari S, Batchelor T, Schiff D, Doherty L, Gigas D, Weiss S, Ramakrishna N, Black P, Ciampa A, Smith ST, Zimmerman J, Ostrowsky L, David K, Wen P. Pilot safety study of lenalidomide and radiation therapy in patients with newly diagnosed glioblastoma. *Neurology* 2007;68:A289.
33. **Wong ET**, Yu M, Song S, Jeyapalan S, Groves M, Swanson K, Gautam S. Vascular endothelial growth factor and matrix metalloprotease in lymphomatous meningitis. *Proceedings of the American Society of Clinical Oncologists Annual Meeting* 2008;26:97s.
34. Wen PY, Macdonald D, van den Bent M, Reardon DA, Galanis E, Cloughesy TF, Lamborn KL, Degroot J, Gilbert MR, Wick W, Tsien C, Mikkelsen T, Chamberlain MC, **Wong ET**, Sorensen AG, Vogelbaum MA, Chang S. Proposal for updated response criteria in malignant gliomas. *Neuro-Oncology* 2009;11:622-623.
35. Drappatz J, Brenner A, Rosenfeld S, Schiff D, Wen PY, Mikkelsen T, Groves M, **Wong ET**, Eichler A, Bouchard D, Neale A, Castaigne JP. ANG1005: A promising new engineered peptide compound (EPIC) for patients with malignant glioma. *Neuro-Oncology* 2009;11:623.
36. **Wong ET**, Barron L, Bloom J, Hackney D, Alsop D. Phase I study of metronomic temozolomide and arterial spin labeling perfusion measurements for recurrent glioblastoma multiforme. *Neuro-Oncology* 2009;11:631.
37. Drappatz J, Norden A, **Wong ET**, Doherty L, LaFrankie D, Ciampa A, Kesari S, Sceppa C, Gerard M, Phan P, Lassman AB, Schiff D, Batchelor T, Ligon KL, Young G, Muzikansky A, Weiss S, Wen PY. Phase I study of vandetanib with radiation therapy and temozolomide for newly diagnosed glioblastoma. *Neuro-Oncology* 2009;11:634.
38. Swanson K, Lok E, Song S, Dessain J, **Wong ET**. Cerebrospinal fluid (CSF) biomarkers for breast cancer (BC) brain metastases. *Annals of Neurology* 2009;66 (Supplement 13):S58.
39. **Wong ET**, Barron L, Bloom J, Hackney D, Alsop D. Arterial spin labeling (ASL) perfusion imaging for anti-angiogenic drug treatment of malignant gliomas. *Sixth Annual World Congress for Brain Mapping and Image Guided Therapy*, August 26, 2009, Boston, MA.
40. Swanson K, Lok E, Song S, Dessain J, **Wong ET**. Cerebrospinal fluid (CSF) biomarkers for breast cancer (BC) brain metastases. *The Sixth Annual Symposium of the Dana Farber/Harvard Cancer Center Program in Breast Cancer*, March 6, 2009, Boston, MA.
41. Drappatz J, Norden A, **Wong ET**, Doherty L, LaFrankie D, Lassman AB, Gerard M, Phan P, Schiff D, Wen PY. Phase I study of vandtanib with radiation therapy and temozolomide for newly-diagnosed glioblastoma. *Proceedings of the American Society of Clinical Oncologists Annual Meeting* 2009;27:94s (Abstract 2031).

42. Recht L, Mechtler L, Phuphanich S, Hormigo A, Hines V, Milstead R, O'Connor PC, Ryan RP, **Wong ET**. A placebo-controlled study investigating the dexamethasone sparing effects of corticorelin acetate in patients with cerebral tumors and peritumoral edema. Proceedings of the American Society of Clinical Oncologists Annual Meeting 2009;27:106s (Abstract 2078).
43. Mechtler L, **Wong ET**, Hormigo A, Pannullo S, Hines V, Milsted R, O'Connor PC, Ryan RP, Recht L. A long-term open-label extension study examining the steroid-sparing effects of corticorelin acetate in patients with cerebral tumors. Proceedings of the American Society of Clinical Oncologists Annual Meeting 2009;27:106s (Abstract 2079).
44. Castaigne JP, Mikkelsen T, Schiff D, Wen P, Rosenfeld S, Groves M, **Wong ET**, Elian KM, Neale A, Lawrence B, Drappatz J. ANG1005 (Angiopep-2/paclitaxel conjugate) as a promising new drug therapy for patients with malignant glioma. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research; 2009 April 18-22, Denver, CO. Philadelphia (PA): AACR 2009. Abstract 3781.
45. Ram Z, Gutin P, Stupp R, and EF-11 Study Investigators. Subgroup and quality of life analyses of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma. *Neuro-Oncology* 2010;12 (Suppl 4):NO-55.
46. **Wong ET**, Gautam S, Malchow C, Lun M, Pan, E, Brem S. bevacizumab for recurrent glioblastoma multiforme: A meta-analysis. *Neuro-Oncology* 2010;12 (Suppl 4):NO61.
47. Lun M, Gautam S, Wu E, **Wong ET**. The natural history of extracranial metastasis from glioblastoma multiforme. *Annals of Neurology* 2010;68 (Suppl 14):S61.
48. **Wong ET**, Gautam S, Malchow C, Lun M, Pan E, Brem S. Brevacizumab for recurrent glioblastoma multiforme: A meta-analysis. *Annals of Neurology* 2010;68 (Suppl 14):S61-62.
49. Song SS, Malchow C, Lok E, Swanson K, **Wong ET**. Cerebrospinal fluid vascular endothelial growth factor (VEGF) in patients with brain metastases from breast cancer. Proceedings of the Annual Meeting of the American Association for Cancer Research 2010;51:351.
50. Locasale JW, Melman T, Song SS, Yang X, Swanson KD, Cantley LC, Asara JM, **Wong ET**. Metabolomics profiling of patient cerebrospinal fluid identifies signatures of malignant glioma. *Neuro-Oncology* 2011;13:69.
51. Lee SX, Swanson KD, **Wong ET**. Mitosis interference of cancer cells during anaphase by electric field from NovoTTF-100A. *Neuro-Oncology* 2011;13:13-14.
52. **Wong ET**, Ram Z, Gutin PH, Stupp R. Updated survival data of the phase III clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma. *Neuro-Oncology* 2011;13:87.
53. Ram Z, **Wong ET**, Gutin PH, Stupp R. Comparing the effect of NovoTTF to bevacizumab in recurrent GBM: a post-hoc sub-analysis of the phase III trial data. *Neuro-Oncology* 2011;13:52.
54. Lok E, Chung AS, Lee S, Melman T, Swanson KD, **Wong ET**. Cerebrospinal fluid

chemokine/cytokine biomarkers for melanoma brain metastasis. *Annals of Neurology* 2011;70:S94.

55. Yu AT, Teich DL, **Wong ET**. Superior semicircular canal dehiscence and osteoporosis in elderly Asian Women. *Annals of Neurology* 2011;70:S84.
56. Yu AT, Teich DL, **Wong ET**. Superior semicircular canal dehiscence and osteoporosis in elderly Asian Women. *Neurology* 2011;76 (Supplement 4):A279.
57. Breitkopf S, Yang X, Locasale J, Rahal R, Yuan M, Wu CL, **Wong E**, Spentzos D, Asara JM. Cancer cell metabolomics from cell lines, in vivo tumor tissue, and preserved fixed tissue. The American Society for Mass Spectrometry Annual Conference, Denver, Colorado, 2011.
58. Breitkopf S, Spentzos D, Wu CL, **Wong E**, Asara J. Metabolomics in the clinic: Case studies with glioblastoma cerebrospinal fluid and formalin fixed paraffin embedded AML, LAM, and osteosarcoma tissue. Human Proteome Organisation 10th Annual World Congress, Geneva, Switzerland, 2011.
59. Gerard M, Drappatz J, Kesari S, **Wong E**, Fadul CE, Norden AD, Quant EC, Weiss SE, Ruland S, Ciampa AS, Doherty LM, LaFrankie DC, Muzikansky A, Sceppa C, Smith KH, Hammond S, Wen PY. Interim analysis of a randomized placebo-controlled pilot trial of armodafinil for fatigue in patients with malignant gliomas undergoing radiotherapy with or without standard chemotherapy treatment. *Proceeding of the American Society of Clinical Oncologists Annual Meeting* 2011.
60. Quant EC, Batchelor TT, Lassman AB, Schiff DS, Kaley TJ, **Wong ET**, Mikkelsen T, Drappatz J, Norden AD, Beroukhim R, Weiss SE, Alexander BM, Sceppa C, Gerard M, Hallisey SD, Bochacki CA, Smith KH, Muzikansky AM, Wen PY. A multicenter, phase II, randomized, non-comparative clinical trial of radiation and temozolomide with or without vandetanib in newly diagnosed glioblastoma (GBM). *Proceeding of the American Society of Clinical Oncologists Annual Meeting* 2011 (in press).
61. Drappatz J, Kesari S, **Wong E**, Fadul C, Norden A, Quant E, Weiss S, Ruland S, Ciampa A, Doherty L, LaFrankie D, Muzikansky A, Hammond S, Wen P. Interim results of a randomized placebo-controlled pilot trial of armodafinil for fatigue in patients with malignant gliomas undergoing radiotherapy with or without standard chemotherapy treatment. *Neurology* 2011;76:A99.
62. Hammond S, Norden AD, Drappatz J, Phuphanich S, Reardon D, **Wong ET**, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor TT, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa A, Doherty L, LaFrankie D, Ruland S, Smith KH, Gerard M, Sceppa C, Wen PY. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. *Neurology* 2011;76:A95.
63. **Wong ET**, Villano JL, Engelhardt HH, Ram Z, Gutin PH. Analysis of the response profile to NovoTTF-100A treatment in patients with recurrent GBM: time to effect, response duration and transient progression in the EF-11 phase III trial. *Neuro-Oncology* 2012;14(Supplement 6):vi74.
64. Lee SX, Tunkyi A, **Wong ET**, Swanson KD. Mitosis interference of cancer cells by NovoTTF-100A causes decreased cellular viability. *Neuro-Oncology* 2012;14(Supplement 6):vi9.

65. Balaj L, Lok E, Swanson KD, Asara J, Chen C, Hochberg F, Breakefield XO, **Wong ET**. Malignant Glioma Genotyping by CSF 2-Hydroxyglutarate Oncometabolite and IDH1 Mutation Analysis. *Annals of Neurology* 2012;72 (Suppl 16):S123.
66. Fonkem E, Robison D, Lok E, Gautam S, **Wong ET**. The natural history of intravascular lymphoma. *American Society of Clinical Oncologists Annual Meeting Abstract* 2012;e18541.
67. Lee SX, Tunkyi A, **Wong ET**, Swanson KD. Mitosis interference of cancer cells during anaphase by electric field from NovoTTF-100A: an update. *American Society of Clinical Oncologists Annual Meeting Abstract* 2012;30:e21078.
68. Fonkem E, Robison D, Lok E, Gautam S, **Wong ET**. The natural history of intravascular lymphoma. *Neurology* 2012;78:P06.020.
69. Bricker P, **Wong ET**, Fonkem E. Spectrum of neurologic presentations of intravascular lymphoma (IVL). *Annals of Neurology* 2012;74(Supplement 17):S86.
70. **Wong ET**, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD. Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure. *Annals of Neurology* 2012;74(Supplement 17):S87.
71. Lee SX, **Wong E**, Swanson KD. Disruption of cell division within anaphase by tumor treating fields (TTFields) leads to immunogenic cell death. *Neuro-Oncology* 2013;15(Supplement 3):iii66-iii67.
72. Kanner AA, **Wong ET**, Villano JL, Ram. Tumor treating fields (TTFields) in recurrent GBM. An update subgroup analysis of the phase III data. *Neuro-Oncology* 2013;15(Supplement 3):iii114.
73. Norden A, Hammond S, Drappatz J, Phuphanich S, Reardon D, **Wong E**, Plotkin S, Lesser G, Raizer J, Batchelor T, Lee E, Kaley T, Muzikansky A, Doherty L, LaFrankie D, Ruland S, Smith K, Gerard M, McCluskey C, Wen P. Phase II study of monthly parsireotide LAR (SOM230C) for recurrent or progressive meningioma: final results. *Neuro-Oncology* 2013;15(Supplement 3):iii123.
74. **Wong ET**, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD. Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure. *Neuro-Oncology* 2013;15(Supplement 3):iii134.
75. Elzinga G, Chung A, **Wong ET**. Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas. *Neuro-Oncology* 2013;15(Supplement 3):iii134.
76. Lacouture M, Davis ME, Elzinga G, Butowski N, Tran D, Villano J, **Wong E**. Dermatologic event characteristics and management with the NovoTTF-100A system, a novel anti-mitotic device for the treatment of recurrent glioblastoma (rGBM). *Neuro-Oncology* 2013;15(Supplement 3):iii229.
77. **Wong ET**, Elzinga G, Chung A, Barron L, Bloom J, Swanson KD. Objective response in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab

- failure. *Neuro-Oncology* [abstract #NO-146] 2013;15(Suppl. 3):iii134.
78. Elzinga G, Chung A, **Wong ET**. Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas. *Neuro-Oncology* [abstract #NO-147] 2013;15(Suppl. 3):iii134.
 79. Pedersen N, Lok E, **Wong ET**. Decreased cerebrospinal fluid (CSF) hypocretin 1 (Orexin A) levels after whole brain radiotherapy: a candidate biomarker for radiation encephalopathy. *Neurology* 2013;80(Meeting Abstract 1):P02.164.
 80. **Wong E**, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman FS, Taillibert S, Ram Z, Villano JL. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. *Journal of Clinical Oncology* 2013;31(May 20 Supplement):2080.
 81. Elzinga G, Chung A, **Wong ET**. Safety analysis of bevacizumab plus NovoTTF-100A in patients with recurrent malignant gliomas. *Journal of Clinical Oncology* 2013;31(May 20 Supplement):2082.
 82. **Wong ET**, Lok E, Elzinga G, Gautam S, Swanson KD. Dexamethasone interferes with alternating electric fields (TTFields) therapy for recurrent glioblastoma. *Neuro-Oncology* 2014;16 (Supplement 5):v22.
 83. **Wong ET**, Englehard HH, Tran DD, Kew Y, Mrugala MM, Cavaliere R, Villano JL, Bota DA, Rudnick J, Sumrall AL, Zhu JJ. An updated analysis of patient registry data on NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma. *Neuro-Oncology* 2014;16 (Supplement 5):v74.
 84. Yang A, Holtzman T, Lee SX, **Wong E**, Swanson KD. Alternating electric fields perturb the localization of cytokinetic furrow proteins and cause aberrant mitotic exit. *Neuro-Oncology* 2014;16 (Supplement 5):v94.
 85. **Wong ET**, Englehard HH, Tran DD, Kew Y, Mrugala MM, Cavaliere R, Villano JL, Bota DA, Rudnick J, Sumrall AL, Zhu JJ. NovoTTF-100A alternating electric fields therapy for recurrent glioblastoma: An analysis of patient registry data. *Canadian Journal of Neurological Sciences* 2014;41:S9.
 86. Zhang K, Bhatia A, Lok E, **Wong ET**. Primary spinal cord glioblastoma: A systemic review. *Canadian Journal of Neurological Sciences* 2014;41:S14.
 87. Vo H, Bhatia A, Lok E, **Wong ET**. T-cell primary central nervous system lymphoma: A systemic literature analysis. *Canadian Journal of Neurological Sciences* 2014;41:S14-S15.
 88. Lee E, Muzikansky A, Kesari S, **Wong E**, Fadul C, Reardon D, Norden A, Nayak L, Rinnie M, Alexander B, Arvold N, Doherty L, LaFrankie D, Pulverenti J, Smith K, Gaffey S, Kenney A, Hammond S, Drappatz J, Wen P. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. *Neuro-Oncology* 2014;16 (Supplement 5):v206.
 89. **Wong ET**, Lok E, Elzinga G, Gautam S, Swanson KD. Dexamethasone interferes with alternating

- electric fields (TTFields) therapy for recurrent glioblastoma. *Annals of Neurology* 2014;76 (Supplement 18):S71.
90. Lok E, Hua V, **Wong ET**. Sensitivity analysis of permittivity and conductivity in alternating electric fields therapy for recurrent glioblastoma. *Neuro-Oncology* 2015;17(Supplement 5):v200.
 91. **Wong ET**, Phung M, Barron L, Lok E. Updated safety analysis of bevacizumab plus alternating electric fields therapy in patients with recurrent malignant gliomas. *Neuro-Oncology* 2015; 17(Supplement 5):v174.
 92. Lai G, Mahadevan A, Hackney D, Warnke P, Kasper E, **Wong E**, Carter B, Chen C. Diagnostic accuracy of PET, SPECT, and ASL in differentiating tumor recurrence from necrosis in cerebral metastasis post-stereotactic radiosurgery. *Neuro-Oncology* 2015; 17(Supplement 5):v46.
 93. Lok E, Hua V, **Wong ET**. Sensitivity analysis of permittivity and conductivity in alternating electric fields therapy for recurrent glioblastoma. *Annals of Neurology* 2015;78(Supplement 19):S72.
 94. Lok E, Hua V, **Wong ET**. Sensitivity analysis of permittivity and conductivity in alternating electric fields therapy for recurrent glioblastoma. In Eastern Neuroradiology Society 27th Annual Meeting, Newport, Rhode Island, September 4-7, 2015.
 95. Phung M, Xu O, Hua V, Lok E, **Wong ET**. Sensitivity analysis of permittivity and conductivity in alternating electric fields therapy for recurrent glioblastoma. In 13th International Symposium on Computer Methods in Biomechanics and Biomedical Engineering (CMBBE2015) and CMBBE Imaging and Visualization 2015, Montreal, Quebec, Canada, September 1-5, 2015.
 96. Phung M, Hua V, Lok E, **Wong ET**. Disposition analysis of computed modeling of alternating electric fields therapy for recurrent glioblastoma. In 13th International Symposium on Computer Methods in Biomechanics and Biomedical Engineering (CMBBE2015) and CMBBE Imaging and Visualization 2015, Montreal, Quebec, Canada, September 1-5, 2015.
 97. Mahadevan A, Barron L, Floyd SR, Kasper E, **Wong ET**. Survival benefit of tumor treating fields plus stereotactic radiosurgery for recurrent malignant gliomas. *American Society of Clinical Oncologists Annual Meeting* 2015, Chicago, Illinois, May 29-June 2, 2015.
 98. **Wong E**, Barron L, Hwong J, Wagner A. Antimitotic NovoTTF Therapy for a progressive glioblastoma patient with Fournier gangrene: Non-interference with wound healing and why it works. *Neurology* 2015;84(14 Supplement):P3-129.
 99. Wang F, Remke M, Bhat K, **Wong E**, Zhou S, Ramaswamy V, Dubuc A, Fonkem E, Salem S, Zhang H, Hsieh T, O'Rourke S, Wu L, Li D, Hawkins C, Kohane I, Wu J, Wu M, Taylor M, Wu E. A micro-RNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. *American Association for Cancer Research Annual Meeting*, Philadelphia, Pennsylvania, April 18-22, 2015.
 100. Lok E, Hua V, **Wong ET**. Sensitivity analysis of permittivity and conductivity on Tumor Treating Fields therapy for recurrent glioblastoma. *Neurology* 2016;86:P6.302.

101. San P, Timmons J, Lok E, Swanson KD, **Wong ET**. Analysis of glioblastoma physical characteristics in patients benefiting from tumor treating electric fields therapy. *Neurology* 2016;80 (Suppl 20):S70.
102. San P, Timmons J, Lok E, Swanson KD, **Wong ET**. Analysis of glioblastoma physical characteristics in patients benefiting from tumor treating electric fields therapy. *Canadian Journal of Neurological Sciences* 2016; 43 (Suppl 4) :S19.
103. San P, Timmons J, Lok E, Swanson KD, **Wong ET**. Analysis of glioblastoma physical characteristics in patients benefiting from tumor treating electric fields therapy. *Neuro-Oncology* 2016;18 (Suppl 6):vi177-vi178.
104. **Wong ET**, Fong J, Lok E, Gautam S. Compliance of Tumor Treating Fields therapy and overall survival in glioblastoma. *Neuro-Oncology* 2016;18 (Suppl 6):vi178.
105. Holtzman T, **Wong E**, Swanson KD. Tumor Treating Fields exposure of tumor cells induce activation phenotype in immune cells. *Neuro-Oncology* 2016;18 (Suppl 6):vi92.
106. **Wong ET**, Fong J, Lok E, Gautam S. Compliance of Tumor Treating Fields therapy and overall survival in glioblastoma. *Neurology* 2017;88:P1.166.
107. San P, Timmons J, Lok E, Swanson KD, **Wong ET**. Analysis of glioblastoma physical characteristics in patients benefiting from Tumor Treating Fields therapy. *Neurology* 2017;88:P1.178.
108. Lok E, San P, **Wong ET**. Tumor Treating Fields distribution in glioblastoma volume depends on conductivity parameters. *Neurology* 2017;88:P5.169.
109. Fong J, Lok E, Swanson KD, **Wong ET**. Breast cancer brain metastases alter chemokine and cytokine profiles in the cerebrospinal fluid. *Neurology* 2017;88:P5.171.
110. Martucci M, McIluff C, Nam JY, Shin C, Phillips K, Greenstein P, Uhlmann E, **Wong E**, Rutkove S. Quantitative ultrasound reveals the impact of corticosteroids on skeletal muscle. *Neurology* 2017;88:S54.001.
111. Ho KG, Uhlmann EJ, Varma H, **Wong ET**. Paraneoplastic gastrointestinal dysmotility syndrome in a patient with glioblastoma. *Annals of Neurology* 2017;82(Suppl 21):S206.
112. Timmons JJ, San P, Bui K, Lok E, **Wong ET**. Semi-automated MRI segmentation workflow for glioblastoma treated by Tumor Treating Fields. *Annals of Neurology* 2017;82(Suppl 21):S207-S208.
113. **Wong E**, Fong J, Xu O, Swanson K. Modulation of cancer cell metabolism and immune phenotype by TTFields. *Neuro-Oncology* 2017;19(Suppl 6):vi251.
114. Timmons JJ, Lok E, San P, Bui K, **Wong ET**. End-to-end workflow for finite element analysis of Tumor Treating Fields in glioblastomas. *Neuro-Oncology* 2017;19(Suppl 6):vi220.

115. Timmons J, Lok E, San P, Bui K, **Wong ET**. Semi-automated MRI segmentation workflow for glioblastoma treated by Tumor Treating Fields. *Neurology* 2018; 90(Suppl 15) P6.162.
116. Ho KWG, **Wong ET**, Uhlmann EJ. Leukopenia as a possible biomarker for overall survival in glioblastoma patients treated with temozolomide. *Neurology* 2018;90(Suppl 15):P6.167.
117. Lok E, San P, White V, **Wong ET**. Comparative analysis of Tumor Treating Fields using conventional versus alternative array placement for posterior fossa glioblastoma. *Annals of Neurology* 2018;84(Suppl 22):S123.
118. Ahluwalia D, Reardon D, Abad A, Curry W, **Wong E**, Peereboom D, Belal A, Qiu J, Mogensen K, Schilero C, Casucci D, Mechtler L, Uhlmann E, Ciesielski M, Fenstermaker R. Phase II trial of a surviving vaccine (SurVaxM) for newly diagnosed glioblastoma. *Neuro-Oncology* 2018;20(Suppl 6):vi10.
119. Lok E, San P, White V, **Wong ET**. Comparative analysis of Tumor Treating Fields using conventional versus alternative array placement for posterior fossa glioblastoma. *Neuro-Oncology* 2018;20(Suppl 6):vi227-vi228.
120. Ahluwalia M, Peereboom D, Schilero C, Forst D, **Wong E**, Wen P, Reardon D. Randomized phase 2 open label study of nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in recurrent glioblastoma. *Neuro-Oncology* 2018;20(Suppl 6):vi234.
121. Ahluwalia D, Reardon D, Abad A, Curry W, **Wong ET**, Belal A, Qiu J, Mogensen K, Schilero C, Hutson A, Casucci D, Mechtler L, Uhlmann EJ, Ciesielski M, Fenstermaker R. SurVaxM with standard therapy in newly diagnosed glioblastoma, phase 2 trial update. *Journal of Clinical Oncology* 2019;37(suppl; abstr 2016).
122. Sarangi S, **Wong E**. Comparing outcomes of adult diffuse midline gliomas to glioblastoma (GBM) in young patients. *Neuro-Oncology* 2019;21(Suppl 6):vi112-vi113.
123. Sarangi S, Zhang D, Dong A, Lok E, **Wong E**. CSF metabolomics as a predictor of survival in patients with brain metastasis receiving immunotherapy. *Neuro-Oncology* 2020;22(Suppl 2):ii105.
124. Stuhlmiller TJ, Shapiro M, Wasserman A, Osking Z, Shrager J, Federowicz B, Warner MJ, Friedland J, Musella A, Blondin NA, Fonkem E, **Wong ET**, Kesari S. XCELSIOR: A real-time real-world learning platform for advance cancer with a direct-to-patient decentralized clinical research infrastructure. *Neuro-Oncology* 2021 (in press).